Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
04/16/14Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 16, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on... 
Printer Friendly Version
04/08/14Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS® (Brentuximab Vedotin) in Key Countries
$6 Million in Milestone Payments Triggered by Achieving First Commercial Sales of ADCETRIS in Australia, South Korea and Mexico for Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 8, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result... 
Printer Friendly Version
04/07/14Seattle Genetics Highlights Antibody-Drug Conjugate (ADC) Program and Technology Advances at AACR
-Seattle Genetics’ ADC Technology Featured in More Than 15 Presentations- -Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 7, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meetin... 
Printer Friendly Version
02/27/14Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings
-Interim Data Demonstrate 92 Percent Objective Response Rate in Ongoing Phase 1/2 Clinical Trial Evaluating ADCETRIS in Combination with Bendamustine for the Treatment of Salvage Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data at the 2014 Bone Marrow Transplant (BMT) Tandem Meetings being held February 26 to March 2, 2014, in Dallas, T... 
Printer Friendly Version
02/11/14Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results
-Total 2013 Revenues of $269.3 Million, Including $144.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Data Anticipated in 2014 from ADCETRIS Phase 3 AETHERA Trial and SGN-CD19A and SGN-CD33A Pipeline Programs- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 11, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quart... 
Printer Friendly Version
02/10/14Seattle Genetics Announces Executive Promotions and Management Addition
-Commercial Leadership Promotions for Chris Boerner to Executive Vice President, Commercial and Charles Romp to Senior Vice President, Sales- -Legal Group Promotions for Kirk Schumacher to Senior Vice President, Legal Affairs and Compliance and General Counsel and Mark Sandbaken to Vice President, Intellectual Property- -David Fontana Named Vice President, Portfolio and Program Management and ADCETRIS® (Brentuximab Vedotin) Program ... 
Printer Friendly Version
02/06/14Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 6, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Leerink Swann Global Healthcare Conference ... 
Printer Friendly Version
02/05/14Seattle Genetics Achieves Sales Milestone Under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda
-$5 million milestone payment triggered by annual ADCETRIS net sales exceeding $100 million in Takeda territories- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 5, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN), today announced that it will receive a $5 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda). The milestone was triggered by Takeda surpassing annual ADCETRIS net ... 
Printer Friendly Version
01/23/14Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2013 Financial Results on February 11, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 23, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2013 financial results on Tuesday, February 11, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/17/14Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
- New Drug Approval of ADCETRIS will Trigger Milestone Payments to Seattle Genetics Totaling $9 Million Upon Final Pricing Agreement in Japan - BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 17, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare (MHLW) fo... 
Printer Friendly Version
01/13/14Seattle Genetics Highlights Key 2014 Milestones and Activities at J.P. Morgan Healthcare Conference
- Phase 3 ADCETRIS® (Brentuximab Vedotin) AETHERA Study Data to be Reported in the Second Half of 2014 - - Data Presentations Anticipated in 2014 from a Broad Portfolio of Antibody-Drug Conjugate Programs, including ADCETRIS, SGN-CD19A and SGN-CD33A - BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted several anticipated 2014 milestones related to ADCETRIS (brentuximab vedoti... 
Printer Friendly Version
01/13/14Seattle Genetics Appoints John A. Orwin to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that John A. Orwin has been appointed to the company’s Board of Directors. Mr. Orwin is a biotechnology and pharmaceutical industry veteran with nearly 25 years of experience, including senior leadership positions in many commercial oncology organizations. He currently serves as Chief Executive Officer of Relypsa, a clinical-stage pharmaceutical company.... 
Printer Friendly Version
01/08/14Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 8, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has further expanded its antibody-drug conjugate (ADC) collaboration with AbbVie (NYSE: ABBV). Under the expanded deal, AbbVie will pay an upfront fee of $25 million for additional rights to utilize Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets, including access to Seattle Genetics’ pyrrolobenzodiazepine ... 
Printer Friendly Version
01/06/14Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 9:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
12/10/13Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Phase 2 Clinical Data in Diffuse Large B-cell Lymphoma (DLBCL) at ASH 2013
-42 Percent Objective Response Rate in Relapsed or Refractory DLBCL, the Most Common Subtype of Non-Hodgkin Lymphoma- -11.5 Month Median Duration Among DLBCL Patients who Achieved Complete Remission- NEW ORLEANS--(BUSINESS WIRE)--Dec. 10, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updated results from a phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in diffuse large B-cell lymphoma (DLBCL) and other B... 
Printer Friendly Version
12/09/13Seattle Genetics Highlights Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2013
-Interim Data Presented from ADCETRIS Phase 2 Clinical Trial in Previously Untreated HL Patients Age 60 or Older- -Updated ADCETRIS Data Presented from Frontline MTCL Phase 1 Clinical Trial and Investigator-Sponsored Relapsed CTCL Phase 2 Clinical Trial- NEW ORLEANS--(BUSINESS WIRE)--Dec. 9, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today summarized ADCETRIS (brentuximab vedotin) data in Hodgkin lymphoma (HL) and non-Hodgkin lymphom... 
Printer Friendly Version
12/09/13Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
- Median Overall Survival of 40.5 Months in Relapsed/Refractory Hodgkin Lymphoma Patients - - Estimated Three Year Survival Rate of 63 Percent with Median Overall Survival Not Yet Reached in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma - NEW ORLEANS--(BUSINESS WIRE)--Dec. 9, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated overall surv... 
Printer Friendly Version
12/07/13Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013
-Ongoing Phase 1 Clinical Trial of SGN-CD19A Demonstrates Encouraging Activity and Safety Profile in Patients with Acute Lymphoblastic Leukemia- NEW ORLEANS--(BUSINESS WIRE)--Dec. 7, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including acute lymphoblastic leukemia (ALL), at the 55th Am... 
Printer Friendly Version
11/11/13Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013
-Data Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Positive Malignancies- -Advancing ADC Technology with Clinical Updates from SGN-CD19A and Genentech Phase 1 ADC Collaborator Programs- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 11, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposi... 
Printer Friendly Version
11/06/13Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 6, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Credit Suisse Healthcare Conference Tuesday, November 12, 9:00 a.m. Mountain Time, Scottsdale... 
Printer Friendly Version
11/05/13Seattle Genetics Reports Third Quarter 2013 Financial Results
-Total Revenues of $71.0 Million, Including $36.5 Million in ADCETRIS® (Brentuximab Vedotin) Net Product Sales- -Multiple ADCETRIS Clinical Data Presentations Planned for ASH Annual Meeting- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 5, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2013. The compan... 
Printer Friendly Version
10/21/13Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A, for Patients with LIV-1-Positive Metastatic Breast Cancer
- LIV-1 is Expressed in 92 Percent of Evaluated Breast Tumors - BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 21, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced the initiation of a phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A utilizes Seattle Genetics’ industry-leading antibody-drug conjugate (ADC) technology. The trial is designed to assess the safety and antitumor activ... 
Printer Friendly Version
10/15/13Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5, 2013
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 15, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
10/11/13Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma
- ADCETRIS Featured in More Than 10 Presentations - - Data from ADCETRIS Phase 1 Frontline Hodgkin Lymphoma (HL) Clinical Trial Support Enrollment of Ongoing Global Phase 3 ECHELON-1 Clinical Trial for Patients with Advanced Frontline HL - BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 11, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations at the 9th International Sym... 
Printer Friendly Version
10/02/13Seattle Genetics Announces Clinical Leadership Appointments
-Jonathan Drachman, M.D., Promoted to Chief Medical Officer and Executive Vice President, Research and Development- -Eric Sievers, M.D., Promoted to Senior Vice President, Clinical Development- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 2, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Jonathan Drachman, M.D., has been promoted to Chief Medical Officer and Executive Vice President, Research and Development. Dr. Drachman j... 
Printer Friendly Version
09/04/13Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 4, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013, at 2:05 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
08/15/13Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma (DLBCL)
-Encouraging Data from Single-Agent Trial in Relapsed DLBCL Support Further Evaluation of ADCETRIS in the Frontline DLBCL Setting- BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 15, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline therapy, for newly diagnosed patients with diffuse large B-ce... 
Printer Friendly Version
07/31/13Seattle Genetics Reports Second Quarter 2013 Financial Results
-Total Revenues of $73.6 Million, Including $35.7 Million in ADCETRIS® (Brentuximab Vedotin) Net Product Sales- -Company Executing on Broad ADCETRIS Clinical Development Plan and Advancing Robust Antibody-Drug Conjugate (ADC) Product Pipeline- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 31, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and ... 
Printer Friendly Version
07/17/13Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2013 Financial Results on July 31, 2013
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 17, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2013 financial results on Wednesday, July 31, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
07/15/13Seattle Genetics Initiates Phase 1 Trial of SGN-CD33A in Acute Myeloid Leukemia (AML)
- Represents Seattle Genetics’ First Antibody-Drug Conjugate (ADC) Program to Advance into Clinical Trials Utilizing Newest ADC Technology - - SGN-CD33A Demonstrated Preclinical Antitumor Activity in AML in Data Presented at the 2012 American Society of Hematology Annual Meeting - BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 15, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced initiation of a phase 1 clinical trial o... 
Printer Friendly Version
06/27/13Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration
BOTHELL, Wash. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Jun. 27, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies’ existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known ... 
Printer Friendly Version
06/25/13Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer
Seattle Genetics eligible to potentially receive more than $500 million in fees and milestones plus royalties under multi-target deal BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 25, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 milli... 
Printer Friendly Version
06/21/13Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at International Conference on Malignant Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 21, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations at the 12th International Conference on Malignant Lymphoma (ICML) being held June 19-22, 2013 in Lugano, Switzerland. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (... 
Printer Friendly Version
06/19/13Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma
− Analysis showed more than 60 percent of patients achieved longer progression-free survival following treatment with ADCETRIS compared to prior therapy − LUGANO, Switzerland--(BUSINESS WIRE)--Jun. 19, 2013-- Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced data from a post-hoc analysis examining progression-free survival (PFS) following treatment with ADCETRIS® (brentuximab vedotin) ve... 
Printer Friendly Version
06/10/13Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse
Trial Rationale Supported by Encouraging Data Reported on the Activity and Tolerability of ADCETRIS in the Treatment of Salvage HL BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 10, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with bendamustine for patients with Hodgkin lymphoma (HL) after first relapse. The multi-phase study is divided ... 
Printer Friendly Version
06/02/13Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
-ADCETRIS Phase 3 ECHELON-1 and ECHELON-2 Trials Designed to Redefine Standard of Care for Frontline Treatment of HL and MTCL- -Genentech Presents Encouraging Phase 1 Data from Two ADC Candidates Utilizing Seattle Genetics’ Technology- CHICAGO--(BUSINESS WIRE)--Jun. 2, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted ongoing clinical development programs for ADCETRIS (brentuximab vedotin) in frontline Hodgkin lymphoma (HL... 
Printer Friendly Version
05/29/13Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May. 29, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Jefferies 2013 Global Healthcare Conference ... 
Printer Friendly Version
05/14/13Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDA
sBLA Supports Use of ADCETRIS for Retreatment and Extended Duration of Therapy in Relapsed Hodgkin Lymphoma and Systemic ALCL BOTHELL, Wash.--(BUSINESS WIRE)--May. 14, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplement to the Biologics License Application (sBLA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyon... 
Printer Friendly Version
05/09/13Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May. 9, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Bank of America Merrill Lynch 2013 Health Care Conference ... 
Printer Friendly Version
05/07/13Seattle Genetics Reports First Quarter 2013 Financial Results
-Total Revenues of $57.3 Million, Including $33.9 Million in ADCETRIS® (Brentuximab Vedotin) Net Product Sales- -Continued Strong Execution on ADCETRIS and Product Development Pipeline and Advances with Industry-Leading Antibody-Drug Conjugate (ADC) Technology- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--May. 7, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for... 
Printer Friendly Version
04/18/13Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 18, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on T... 
Printer Friendly Version
04/09/13Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR
- Presentations Highlight Preclinical Data for Novel SGN-CD33A and SGN-LIV1A Programs and Breakthroughs in Research to Develop Highly Stable Linkers and More Potent Chemotypes - - AACR Highlights Phase 1 Data for Genentech’s DMUC5754A, an ADC for Ovarian Cancer Utilizing Seattle Genetics’ Technology - BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 9, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antib... 
Printer Friendly Version
03/18/13Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® (Brentuximab Vedotin) in Relapsed Hodgkin Lymphoma and Systemic ALCL
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 18, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is an antibody-... 
Printer Friendly Version
02/27/13Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Cowen & Company 33rd Annual Health Care Conference Monday, March 4, 2013 at 1... 
Printer Friendly Version
02/12/13Seattle Genetics Reports Fourth Quarter and Year 2012 Financial Results
-ADCETRIS® (Brentuximab Vedotin) Net Product Sales of $35.4 Million in the Fourth Quarter and $138.2 Million for the Year in 2012- -Strong Financial Position with Year-end Cash and Investments of $364.3 Million Enables Company to Continue Broad Expansion of ADCETRIS and Advance Pipeline of Six Other Clinical and Late-Stage Preclinical ADCs- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 12,... 
Printer Friendly Version
02/06/13Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A
- Clinical Trials Evaluating Novel ADC in Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma - - Represents Seattle Genetics’ Fifth Proprietary ADC Program in Ongoing Clinical Trials - BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 6, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one fo... 
Printer Friendly Version
02/01/13Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
- ADCETRIS is the First in a New Class of Targeted Therapies Called Antibody-Drug Conjugates - BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 1, 2013-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications: (1) the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transp... 
Printer Friendly Version
01/29/13Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2012 Financial Results on February 12, 2013
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 29, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2012 financial results on Tuesday, February 12, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/25/13Seattle Genetics Announces Data from ASG-5ME Phase I Clinical Trial for Pancreatic Cancer
- ASG-5ME is a Novel Antibody-Drug Conjugate in Evaluation for the Treatment of Pancreatic, Gastric and Prostate Cancers - BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 25, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) today presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA) at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers ... 
Printer Friendly Version
01/24/13Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)
− Phase III Clinical Trial Designed to Examine the Use of ADCETRIS as Part of a Front-line Treatment Regimen for Newly Diagnosed MTCL Patients, Including Systemic Anaplastic Large Cell Lymphoma and Other Types of Peripheral T-cell Lymphomas − BOTHELL, Wash. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2013-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda ... 
Printer Friendly Version
01/03/13Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 3, 2013-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2013, at 11:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
12/11/12Seattle Genetics Highlights Data Presentations from Genentech ADC Collaborator Programs at ASH Annual Meeting
-Encouraging Phase I Data from Two ADC Programs Utilizing Seattle Genetics’ Technology- ATLANTA--(BUSINESS WIRE)--Dec. 11, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted clinical data from two antibody-drug conjugate (ADC) programs in development by Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) that utilize Seattle Genetics’ technology. The data were presented at the 54th American Society of Hematol... 
Printer Friendly Version
12/10/12Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting
-Two Phase II Trials Demonstrate Greater than 65 Percent Objective Response Rate in Patients with Relapsed CTCL- - Phase III ALCANZA Trial Ongoing to Evaluate ADCETRIS in CTCL - ATLANTA--(BUSINESS WIRE)--Dec. 10, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that results from two ongoing investigator-sponsored phase II clinical trials of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell ly... 
Printer Friendly Version
12/10/12Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
- 96 Percent Complete Remission Rate in Newly Diagnosed Hodgkin Lymphoma Patients Treated with ADCETRIS in Combination with AVD Chemotherapy - - Safety and Response Data Support Ongoing Phase III Trial of ADCETRIS and AVD Chemotherapy in Patients with Newly Diagnosed Hodgkin Lymphoma - ATLANTA--(BUSINESS WIRE)--Dec. 10, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced results from a phase I clinical trial of A... 
Printer Friendly Version
12/10/12Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting
-Novel ADC Candidate Demonstrates Preclinical Antitumor Activity in Acute Myeloid Leukemia- ATLANTA--(BUSINESS WIRE)--Dec. 10, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data from SGN-CD33A, an antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML), at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlant... 
Printer Friendly Version
12/10/12Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting
-Long-Term Follow-up from ADCETRIS Pivotal HL Trial Demonstrates an Estimated Two Year Survival Rate of 65 Percent- -Investigator Analysis Shows Median Overall Survival for ADCETRIS-Treated Relapsed HL Patients after ASCT Was 91 Months Compared with 28 Months among Non-ADCETRIS Patients- -ADCETRIS Activity and Tolerability Observed in the Treatment of Salvage HL and Patients Age 60 and Over with CD30-Positive Hematologic Ma... 
Printer Friendly Version
12/09/12Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL)
-100 Percent Objective Response Rate, Including 88 Percent Complete Remissions, in Newly Diagnosed MTCL Patients Treated with ADCETRIS in Combination with CHP Chemotherapy- -Data Support Planned Phase III Trial in Front-line MTCL, Including Systemic Anaplastic Large Cell Lymphoma and Other Types of Peripheral T-cell Lymphomas- ATLANTA--(BUSINESS WIRE)--Dec. 9, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced results... 
Printer Friendly Version
12/09/12Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies from Multiple Presentations at ASH Annual Meeting
-34 Percent Objective Response Rate in Phase II Trial for Relapsed or Refractory Non-Hodgkin Lymphomas, Including 44 Percent in Diffuse Large B-cell Lymphoma (DLBCL)- -Long-term Follow-up Demonstrates Durable Complete Remissions in Pivotal Systemic ALCL Trial- -Investigator Data Describe CD30 Expression in up to 25 Percent of DLBCL Cases- -Case Studies Indicate Activity of ADCETRIS in Systemic Mastocytosis- ... 
Printer Friendly Version
11/26/12Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides
-Designation Supports Regulatory Strategy for ADCETRIS in CTCL, including Ongoing Phase III ALCANZA Trial- -Investigator Data on ADCETRIS in CTCL to be Presented at Upcoming ASH Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 26, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the tr... 
Printer Friendly Version
11/09/12Seattle Genetics to Present at Credit Suisse Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the upcoming Credit Suisse 2012 Healthcare Conference in Phoenix, Arizona. The presentation is scheduled for Thursday, November 15, at 2:30 p.m. Mountain time. It will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. ... 
Printer Friendly Version
11/07/12Seattle Genetics Reports Third Quarter 2012 Financial Results
-ADCETRIS® Net Product Sales of $33.7 Million in the Third Quarter of 2012 and $102.8 Million Year-to-Date in 2012- -Multiple ADCETRIS Data Presentations Planned for ASH from Clinical Trials in Broad Range of CD30-Positive Malignancies- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 7, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter... 
Printer Friendly Version
11/05/12Seattle Genetics’ ASH 2012 Presentations Highlight ADCETRIS® and Demonstrate Leadership in the Development of Antibody-Drug Conjugates (ADCs)
-Data Support Plans to Establish ADCETRIS as the Foundation of Therapy for a Broad Array of CD30-Positive Malignancies- -Company Announces Novel ADC Candidate SGN-CD33A and Encouraging ADC Collaborator Data Presentations- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 5, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that more than a dozen abstracts, in addition to several collaborator abstracts, for both ADCETRIS (brentuximab vedotin) and investigational antibody-drug conjugates (ADCs) ... 
Printer Friendly Version
11/01/12Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma
− First randomized clinical trial designed to examine the use of ADCETRIS as part of a frontline treatment regimen for patients with previously untreated classical Hodgkin lymphoma − CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 1, 2012-- Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the ini... 
Printer Friendly Version
10/31/12Seattle Genetics Announces ADCETRIS® Receives European Commission Conditional Marketing Authorization
Conditional Marketing Authorization Triggers Milestone Payments to Seattle Genetics Totaling $25 Million BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 31, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its collaborator, Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced that the European Commission has granted conditional marketing authorization for ADCETRIS ... 
Printer Friendly Version
10/24/12Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2012 Financial Results on November 7, 2012
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 24, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter and year-to-date 2012 financial results on Wednesday, November 7, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
10/23/12Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Abbott
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 23, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has expanded its antibody-drug conjugate (ADC) collaboration with Abbott (NYSE:ABT). Under the expanded deal, Abbott will pay an upfront fee of $25 million for rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to additional oncology targets. In addition, Seattle Genetics may receive up to $220 million ... 
Printer Friendly Version
10/17/12Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS® as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 17, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase II clinical trial evaluating ADCETRIS (brentuximab vedotin) as a front-line therapy for patients age 60 or older with newly diagnosed Hodgkin lymphoma (HL). The trial is designed to assess the efficacy and tolerability of ADCETRIS as a monotherapy for older HL patients who have received no prior treatment. Seattle Gen... 
Printer Friendly Version
10/09/12Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 9, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will receive undisclosed milestone payments under its antibody-drug conjugate (ADC) collaboration with Genentech, a member of the Roche Group (SWX:RO) (SWX:ROG) (OTCQX:RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II random... 
Printer Friendly Version
10/01/12Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma
– Preliminary data reported today at the ESMO 2012 Congress (European Society for Medical Oncology) – CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), and Seattle Genetics, Inc. (Nasdaq: SGEN), today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activi... 
Printer Friendly Version
09/25/12Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS® for Post-Transplant Patients with Hodgkin Lymphoma
CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 25, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS (brentuximab vedotin) for post-transplant Hodgkin lymphoma (HL) patients. The phase III trial, also known as the AETHE... 
Printer Friendly Version
09/05/12Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 5, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at three investor conferences in September. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Morgan Stanley Global Healthcare Conference ... 
Printer Friendly Version
08/24/12Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 24, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor®) for patients with advanced metastatic renal cell carcinoma (RCC). The trial is designed to assess the safety and antitumor activity of SGN-75 in combination with everolimus. Seattle Genetics is a leader in the field of antibody-drug conjugates (ADCs) and SGN-75 is an ADC targeted to CD70. "... 
Printer Friendly Version
08/08/12Seattle Genetics Reports Second Quarter 2012 Financial Results
-$34.7 Million in ADCETRIS® Net Product Sales in Second Quarter 2012- -Emerging ADCETRIS Clinical Data Reinforce Potential in Broad Array of CD30-Positive Cancers- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 8, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter ended June 30, 2012. The company also highlighted progress with... 
Printer Friendly Version
07/26/12Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2012 Financial Results on August 8, 2012
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 26, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter and year-to-date 2012 financial results on Wednesday, August 8, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
07/20/12Seattle Genetics Announces ADCETRIS® Receives Positive CHMP Opinion for Conditional Approval in European Union
Recommended as Treatment for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 20, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the Eu... 
Printer Friendly Version
06/14/12Seattle Genetics Highlights Updated Survival Data from ADCETRIS® Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma
– Median Overall Survival Not Reached After 26.5 Month Median Follow-up – – Data to be Presented at the 17th European Hematology Association Annual Meeting – BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 14, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updated survival data from a pivotal clinical trial of single-agent ADCETRIS (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma (HL) ... 
Printer Friendly Version
06/04/12Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer
Dose-Escalation Completed and Preliminary Antitumor Activity Observed SANTA MONICA, Calif. & BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 4, 2012-- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer (CRPC). ASG-5ME is an antibody-drug conjugate (ADC) target... 
Printer Friendly Version
06/02/12Seattle Genetics Announces ADCETRIS® Clinical Data to be Reported in Multiple Presentations at ASCO Annual Meeting
-70 percent objective response rate in retreatment trial- -Multiple objective responses observed in CD30-positive non-Hodgkin lymphoma patients, including four of seven patients with diffuse large B-cell lymphoma- -First report of CD30 expression from comprehensive screening in broad range of non-lymphoma malignancies- CHICAGO--(BUSINESS WIRE)--Jun. 2, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that dat... 
Printer Friendly Version
05/31/12Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May. 31, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Jefferies 2012 Global Healthcare Conference ... 
Printer Friendly Version
05/23/12Seattle Genetics Announces Health Canada Accepts ADCETRIS® New Drug Submission for Review
BOTHELL, Wash.--(BUSINESS WIRE)--May. 23, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission (NDS) for the use of ADCETRIS (brentuximab vedotin) in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). The NDS will be reviewed under the Health Canada policy of Notice of Compliance with Conditions (NOC/c). ADC... 
Printer Friendly Version
05/16/12Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--May. 16, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of the company’s poster presentations is below and full abstracts can be accessed on the ASCO websit... 
Printer Friendly Version
05/11/12Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference
BOTHELL, Wash.--(BUSINESS WIRE)--May. 11, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 1:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics ... 
Printer Friendly Version
05/10/12Seattle Genetics Announces Data from Investigator Trial of ADCETRIS™ in Relapsed Cutaneous T-Cell Lymphoma
-Interim Data Demonstrate 75 Percent Response Rate in Patients with Relapsed CTCL- BOTHELL, Wash.--(BUSINESS WIRE)--May. 10, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being hel... 
Printer Friendly Version
05/08/12Seattle Genetics Reports First Quarter 2012 Financial Results
-$34.5 million of ADCETRIS™ Net Product Sales in First Quarter 2012- -Multiple Ongoing and Planned Clinical Trials of ADCETRIS to Broadly Explore Therapeutic Potential in CD30-Positive Cancers- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--May. 8, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2012. The company also highlighted ... 
Printer Friendly Version
05/07/12Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma
-Trial Conducted Under Special Protocol Assessment with FDA- -Study Includes Evaluation of Companion Diagnostic Test for CD30 Identification- CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--May. 7, 2012-- Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), today announced the initiation of an internationa... 
Printer Friendly Version
04/24/12Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2012 Financial Results on May 8, 2012
BOTHELL, Wash., Apr 24, 2012 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its first quarter 2012 financial results on Tuesday, May 8, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, May 8, 2... 
Printer Friendly Version
04/12/12Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS(TM) in CD30-Positive Malignancies
-Ventana to develop molecular companion diagnostic test to evaluate CD30 expression levels in tissue specimens- BOTHELL, Wash.& CAMBRIDGE, Mass. & TUCSON, Ariz., Apr 12, 2012 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have formed a collaboration with Ventana Medical Systems, Inc. (Venta... 
Printer Friendly Version
04/03/12Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR
-Data Highlights Include New Cell-Killing Agent and Site-Specific Conjugation Technology- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 3, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR) being held in Chicago, IL. The presentations highlighted data from an ADC using ... 
Printer Friendly Version
03/29/12Seattle Genetics to Present at Needham Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 29, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the upcoming 11th Annual Needham Healthcare Conference in New York, NY. The presentation is scheduled for Tuesday, April 3, at 10:00 a.m. Eastern time. It will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. Abou... 
Printer Friendly Version
03/26/12Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology
-Data Supported FDA Accelerated Approval in Relapsed Patients- -Broad Ongoing Evaluation of ADCETRIS in Earlier Lines of Hodgkin Lymphoma and in Other CD30-Positive Malignancies- BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 26, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Journal of Clinical Oncology (JCO) published results of the company’s pivotal clinical trial of ADCETRIS™ (brentuximab vedotin) in Hodgkin ly... 
Printer Friendly Version
03/21/12Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 21, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Nancy A. Simonian, M.D. has been appointed to the company’s Board of Directors. Dr. Simonian is a biotechnology veteran with more than 16 years of global drug development experience, most recently as Chief Medical Officer at Millennium: The Takeda Oncology Company. “Nancy brings significant experience in all aspects of clinical d... 
Printer Friendly Version
02/23/12Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 23, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that management will present at the following upcoming investor conferences. RBC Capital Markets’ 2012 Global Healthcare Conference Tuesday, February 28, 2012 at 11:00 a.m. Eastern time in New York, NY   ... 
Printer Friendly Version
02/23/12Seattle Genetics Provides Update on Commercial Leadership
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 23, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Chris Boerner, Ph.D. has been promoted to Senior Vice President, Commercial. Dr. Boerner joined Seattle Genetics in November 2010 as Vice President, Marketing, and has served as a key member of the commercial organization involved in the launch of ADCETRIS™ (brentuximab vedotin). He replaces Bruce Seeley, former Executive Vice President, Commer... 
Printer Friendly Version
02/13/12Seattle Genetics Reports Fourth Quarter and Year 2011 Financial Results
-$33.2 million of ADCETRIS™ Net Product Sales in Fourth Quarter 2011- -Broad Clinical Program to Evaluate ADCETRIS in CD30-Positive Malignancies; Nine Ongoing Clinical Trials; Three Additional Phase III Trial Initiations Planned- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 13, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year en... 
Printer Friendly Version
02/08/12Seattle Genetics to Present at Upcoming Investor Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 8, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conference. The presentation will be webcast live and available for replay from Seattle Genetics’ website at http://www.seattlegenetics.com in the Investors and News section. Leerink Swann 2012 Global Healthcare Conference Wednesday, February 15, 2012, at 12:00 p.m.... 
Printer Friendly Version
02/01/12Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2011 Financial Results on February 13, 2012
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 1, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2011 financial results on Monday, February 13, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/26/12Seattle Genetics Announces Data from ADCETRIS™ in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
-Interim Data Demonstrate 65 Percent Response Rate in Patients with Relapsed CTCL- -Two Case Studies Provide First Report of Activity and Tolerability in PTCL-NOS Patients- SAN FRANCISCO--(BUSINESS WIRE)--Jan. 26, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lympho... 
Printer Friendly Version
01/26/12Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ in Front-line Mature T-Cell Lymphomas
-Phase III Trial Planned in Front-line Mature T-Cell Lymphomas- SAN FRANCISCO--(BUSINESS WIRE)--Jan. 26, 2012-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company today announced interim results from 32 patients treated to date in a phase I clinical trial of ADCETRIS (brentuximab vedotin) administered in combination with or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic la... 
Printer Friendly Version
01/13/12Seattle Genetics Announces Updates to ADCETRIS™ Prescribing Information
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 2012-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updates to the U.S. Prescribing Information (PI) for ADCETRIS™ (brentuximab vedotin). The revised PI will include the following updated information: A boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving ADCETRIS. ... 
Printer Friendly Version
01/04/12Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 4, 2012-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2012 at 10:30 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at http://www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattle Genetics is ... 
Printer Friendly Version
12/13/11Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
- Phase III Front-line Trial Planned in Advanced Stage Hodgkin Lymphoma Patients - SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2011-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced interim results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma patients. The dat... 
Printer Friendly Version
12/12/11Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS™ (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting
- Updated Data Show Complete Remission Rate of 59 Percent with Median Duration of Complete Remissions Not Yet Reached After Median Follow-Up of 14.7 Months - SAN DIEGO--(BUSINESS WIRE)--Dec. 12, 2011-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today reported updated data from a pivotal trial of single-agent ADCETRIS in rela... 
Printer Friendly Version
12/12/11Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS™ (Brentuximab Vedotin) at ASH Annual Meeting
- Presentations Highlight Positive Findings from Analyses of Patients Receiving Prolonged Treatment with ADCETRIS and Patients Receiving ADCETRIS Prior to Allogeneic Transplant - SAN DIEGO, Dec 12, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data demonstrating that prolonged treatment with ADCETRIS beyond 16 cycles of therapy was associated with clinically meaningful durations of response with a manageable safety ... 
Printer Friendly Version
12/07/11Seattle Genetics to Present at Upcoming Investor Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 7, 2011-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conference. Oppenheimer 22nd Annual Healthcare Conference Wednesday, December 14, 2011 at 2:10 p.m. Eastern Time in New York, NY The presentation will be webcast live and available for replay from Seattle Genetics’ website at http://www.seattlegenetics.com i... 
Printer Friendly Version
11/08/11Seattle Genetics and Millennium Announce Presentation of ADCETRIS(TM) Data at American Society of Hematology Annual Meeting
BOTHELL, Wash. & CAMBRIDGE, Mass., Nov 08, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502), today announced that ADCETRIS(TM) (brentuximab vedotin) will be featured in multiple presentations at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011, in San Diego, Calif. ... 
Printer Friendly Version
11/07/11Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash., Nov 07, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. Credit Suisse Healthcare Conference Wednesday, November 9, 2011 at 11:30 a.m. Mountain time in Phoenix, AZ Lazard Capital Markets 8th Annual Healthcare Conference Tuesday, November 15, 2011 at 11:00 a.m. Eastern time in New York, NY The presentations will be webcast live and av... 
Printer Friendly Version
11/03/11Seattle Genetics Reports Third Quarter 2011 Financial Results
- ADCETRIS(TM) Approved by FDA on August 19, 2011- -$10 million in ADCETRIS Net Product Sales Drives Third Quarter Revenue Growth- -Broad Clinical Program Ongoing to Evaluate ADCETRIS in CD30-Positive Malignancies- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash., Nov 03, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2011. The company also highlight... 
Printer Friendly Version
10/26/11Seattle Genetics Appoints Vice President, Medical Affairs and Announces Vice President, Quality Management Promotion
BOTHELL, Wash., Oct 26, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of James Kyle Bryan, M.D., as Vice President, Medical Affairs. Dr. Bryan is a hematologist and medical oncologist, and brings more than 18 years of experience in oncology drug development. In addition, the company announced the promotion of Charles Smith to Vice President, Quality. Mr. Smith joined Seattle Genetics in 2003, and has played a ... 
Printer Friendly Version
10/25/11Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Lymphoma Malignancies
BOTHELL, Wash., Oct 25, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase II clinical trial of ADCETRIS(TM) (brentuximab vedotin) for patients with CD30-positive non-lymphoma malignancies, including multiple myeloma, leukemia and solid tumors. The trial is designed to assess the antitumor activity and safety profile of ADCETRIS in these patients. ADCETRIS is an antibody-drug conjugate (ADC) directed ... 
Printer Friendly Version
10/20/11Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2011 Financial Results on November 3, 2011
BOTHELL, Wash., Oct 20, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its third quarter 2011 financial results on Thursday, November 3, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday,... 
Printer Friendly Version
09/24/11Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(TM) (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting
- Six out of nine patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma achieved complete remission in phase I and phase II trials - CAMBRIDGE, Mass. & BOTHELL, Wash., Sep 24, 2011 (BUSINESS WIRE) --Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), today reported data from a retrospective analysis... 
Printer Friendly Version
09/13/11Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer
-Companies to combine proprietary technologies to generate novel ADC product candidates- BOTHELL, Wash. & OXFORD, England, Sep 13, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) and Oxford BioTherapeutics (OBT) today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-... 
Printer Friendly Version
09/08/11Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash., Sep 08, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2011 at 11:30 a.m. Eastern time in New York, NY UBS Global Life Sciences Conference Tuesday, September 20, 2011 at 2:30 p.m. Eastern time in New York, NY The presentations will be webcast live and available for replay from Seat... 
Printer Friendly Version
08/23/11Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(TM) in CD30-Positive Non-Hodgkin Lymphoma
BOTHELL, Wash., Aug 23, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has initiated a phase II clinical trial of ADCETRIS(TM) (brentuximab vedotin) for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes. The trial is designed to assess the antitumor activity, duration of response and safety... 
Printer Friendly Version
08/19/11Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS(TM) (Brentuximab Vedotin) for Two Indications
-First in a new class of ADCs to be FDA-approved- -Seattle Genetics to implement comprehensive reimbursement support and patient assistance program- -Conference call Monday, August 22, 2011, at 8:30 a.m. ET to provide further information on the launch and commercialization of ADCETRIS- BOTHELL, Wash., Aug 19, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval... 
Printer Friendly Version
08/04/11Seattle Genetics Reports Second Quarter 2011 Financial Results
-FDA action date of August 30, 2011 for ADCETRIS(TM) BLAs- -Company prepared for planned commercial launch of ADCETRIS- -Increased cash outlook at end of 2011 driven by ADC collaboration activities- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash., Aug 04, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2011. The company also highlighted recent product developmen... 
Printer Friendly Version
07/26/11Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2011 Financial Results on August 4, 2011
BOTHELL, Wash., Jul 26, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its second quarter 2011 financial results on Thursday, August 4, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, ... 
Printer Friendly Version
07/14/11Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS(TM) for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCL
Company to host conference call on Friday, July 15, 2011 at 8:30 a.m. ET BOTHELL, Wash., Jul 14, 2011 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10-0 to recommend that the FDA grant accelerated approval of ADCETRIS(TM) (brentuximab vedotin) for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant (ASCT). In addition, ... 
Printer Friendly Version
07/14/11Trading of Seattle Genetics Common Stock Halted
-Advisory Committee of the Food and Drug Administration to Discuss ADCETRIS(TM) Biologics License Applications- -Company to host conference call on Friday, July 15, 2011 at 8:30 a.m. ET- BOTHELL, Wash., Jul 14, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting today to dis... 
Printer Friendly Version
06/27/11Seattle Genetics Achieves Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA
BOTHELL, Wash., Jun 27, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc., (Nasdaq: SGEN) today announced that it will receive a $5 million milestone payment under its brentuximab vedotin (ADCETRISTM) collaboration with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502). The milestone was triggered by the European Medicines Agency (EMA) acceptance of the Marketing Authorization Applica... 
Printer Friendly Version
06/17/11Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
BOTHELL, Wash., Jun 17, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Eric L. Dobmeier has been promoted to the newly created position of Chief Operating Officer (COO). Mr. Dobmeier has been with Seattle Genetics for more than nine years, serving most recently as Chief Business Officer. "Eric is an invaluable member of the leadership team at Seattle Genetics, and this promotion reflects his significant strategic and ... 
Printer Friendly Version
06/16/11Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
Oncologic Drugs Advisory Committee Meetings Scheduled for July 14, 2011 BOTHELL, Wash., Jun 16, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company's Biologics License Applications (BLAs) for brentuximab vedotin (ADCETRIS(TM)) on July 14, 2011. ODAC plans to review the BLA for the treatment of relapsed or refracto... 
Printer Friendly Version
06/15/11Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Clinical Data at International Conference on Malignant Lymphoma
BOTHELL, Wash., Jun 15, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that data from its brentuximab vedotin (ADCETRIS(TM)) and dacetuzumab (SGN-40) programs will be presented at the 11th International Conference on Malignant Lymphoma (ICML) being held June 15-18, 2011 in Lugano, Switzerland. Two oral presentations on brentuximab vedotin will feature encore data from the recent American Society of Clinical Oncology (ASCO)... 
Printer Friendly Version
06/11/11Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting
Data demonstrate objective responses and complete remissions in relapsed or refractory Hodgkin lymphoma patients who were ineligible for or refused treatment with ASCT CAMBRIDGE, Mass. & BOTHELL, Wash., Jun 11, 2011 (BUSINESS WIRE)-- Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE) and Seattle Genetics, Inc. (Nasdaq), announced today that data on ADCETRIS™ (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma pat... 
Printer Friendly Version
06/10/11Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(TM) (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting
- 14 out of 15 patients (93 percent) achieved complete resolution of malignant cutaneous lesions in phase II systemic ALCL trial - CAMBRIDGE, Mass. & BOTHELL, Wash., Jun 10, 2011 (BUSINESS WIRE) -- Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (Nasdaq: SGEN), today reported data from a sub-analysis of the registration-enabling phase II clinical trial of ADCETRIS(TM) (brentuximab vedotin) in re... 
Printer Friendly Version
06/09/11Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration
BOTHELL, Wash. & SANTA MONICA, Calif., Jun 09, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement. The ADC, known as ASG-22ME (formerly AGS-22M6E), targets the Nectin-4 antigen, which is expre... 
Printer Friendly Version
06/06/11Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
-Median duration of complete remissions greater than 20 months in patients with relapsed or refractory Hodgkin lymphoma- -Median durations of overall responses and complete remissions both greater than one year in patients with relapsed or refractory systemic ALCL- CHICAGO, Jun 06, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ... 
Printer Friendly Version
06/06/11Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting
CHICAGO, Jun 06, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the presentation of interim data from an ongoing phase I clinical trial of SGN-75 in renal cell carcinoma (RCC) and non-Hodgkin lymphoma at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting being held in Chicago, IL. SGN-75 is an antibody-drug conjugate (ADC) targeted to CD70. The interim data suggest that SGN-75 is generally well tolerated ... 
Printer Friendly Version
06/01/11Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash., Jun 01, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. Jefferies 2011 Global Healthcare Conference Tuesday, June 7, 2011 at 12:45 p.m. Eastern time in New York, NY Goldman Sachs 32nd Annual Global Healthcare Conference Wednesday, June 8, 2011 at 11:20 a.m. Pacific time in Rancho Palos Verdes, CA The presentations will be webcast live and a... 
Printer Friendly Version
05/27/11Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association
Two Presentations Highlight Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma CAMBRIDGE, Mass. & BOTHELL, Wash., May 27, 2011 (BUSINESS WIRE) --Millennium: The Takeda Oncology Company and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that an oral presentation and a poster presentation featuring brentuximab vedotin (SGN-35) will be presented at the 16th Congress of ... 
Printer Friendly Version
05/19/11Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical Data at the American Society of Clinical Oncology Annual Meeting
BOTHELL, Wash., May 19, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its brentuximab vedotin (ADCETRIS(TM)) and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology (ASCO) 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL. A summary of the company's ASCO poster presentations is below and full abstracts can be accessed on the ASCO website at www.asco.org. Brentu... 
Printer Friendly Version
05/05/11Seattle Genetics Reports First Quarter 2011 Financial Results
-Brentuximab vedotin PDUFA date set for August 30, 2011- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash., May 05, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the first quarter of 2011. The company also highlighted recent product development activities and upcoming milestones. "The recent action by FDA to accept for filing our Biologics License Applications for brentuximab vedotin in relapsed or refractor... 
Printer Friendly Version
05/02/11Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Priority Review for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
-PDUFA date set for August 30, 2011- BOTHELL, Wash., May 02, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing two Biologics License Applications (BLAs) for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic larg... 
Printer Friendly Version
04/27/11Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash., Apr 27, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. 36th Annual Deutsche Bank Healthcare Conference Tuesday, May 3, 2011 at 8:40 a.m. Eastern time in Boston, MA Bank of America Merrill Lynch Healthcare Conference Tuesday, M... 
Printer Friendly Version
04/26/11Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2011 Financial Results on May 5, 2011
BOTHELL, Wash., Apr 26, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its first quarter 2011 financial results on Thursday, May 5, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, May ... 
Printer Friendly Version
04/19/11Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration
Collaboration expanded with new cancer target Seattle Genetics has co-development option after Phase I Genmab introduces HuMax-CD74 ADC to pre-clinical pipeline COPENHAGEN, Denmark & BOTHELL, Wash., Apr 19, 2011 (BUSINESS WIRE) --Genmab A/S (OMX:GEN) and Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the companies have entered into a second antibody-drug conjugate (ADC) research collaboration agreement. Under the new agr... 
Printer Friendly Version
04/18/11Seattle Genetics Appoints Vice President, Corporate Development and Announces Management Promotion
BOTHELL, Wash., Apr 18, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Natasha Hernday as Vice President, Corporate Development. Ms. Hernday brings 10 years of experience in business and corporate development, including in-licensing, out-licensing and mergers and acquisitions. In addition, the company announced the promotion of Eric Sievers, M.D., to Vice President, Clinical Affairs. Dr. Sievers joined Seatt... 
Printer Friendly Version
04/13/11Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical Development
-Total of 13 Clinical-Stage ADCs Now Utilize Seattle Genetics' Technology- BOTHELL, Wash., Apr 13, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that ten programs utilizing the company's proprietary antibody-drug conjugate (ADC) technology are now in clinical development across its 11 current ADC collaborations. This includes two additional ADC programs for which Investigational New Drug applications were recently submitted... 
Printer Friendly Version
04/06/11Seattle Genetics Reports Brentuximab Vedotin (SGN-35) Data at EBMT Annual Meeting
50 Percent of Post-Allogeneic Transplant Patients Achieved an Objective Response BOTHELL, Wash., Apr 06, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin (SGN-35) following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting in Paris, France. Bre... 
Printer Friendly Version
04/05/11Seattle Genetics Highlights ADC Technology Research at AACR
BOTHELL, Wash., Apr 05, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held in Orlando, FL. The presentations highlighted advances being made by the company with its ADC technology and preclinical research on its ADC pipeline, including brentuximab ... 
Printer Friendly Version
03/30/11Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash., Mar 30, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will present at two upcoming investor conferences. Needham & Company 10th Annual Healthcare Conference Wednesday, April 6, 2011 at 2:00 p.m. Eastern Time (ET) in New York, NY Leerink Swann Cancer Roundtable Conference ... 
Printer Friendly Version
03/22/11Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott
Seattle Genetics to receive $8 million upfront payment, plus potential milestone payments and royalties under single-target collaboration BOTHELL, Wash., Mar 22, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has entered into a collaboration agreement with Abbott (NYSE:ABT) under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with an... 
Printer Friendly Version
03/15/11Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration
BOTHELL, Wash., Mar 15, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration. Seattle Genetics entered into this collaboration with Millennium in April ... 
Printer Friendly Version
03/03/11Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash., Mar 03, 2011 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the following upcoming investor conferences. Cowen & Company 31st Annual Healthcare Conference Wednesday, March 9, 2011 at 11:00 a.m. Eastern time in Boston, MA Barclays Capital 2011 Global Healthcare Conference Wednesday, March 16, 2011 at 3:45 p.m. Eastern time in Miami, FL The presentations will be webcast live and available for replay from Seattle... 
Printer Friendly Version
03/01/11Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL
BOTHELL, Wash., Mar 01, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (ALCL) patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is highly expresse... 
Printer Friendly Version
02/28/11Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL
BOTHELL, Wash., Feb 28, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of ... 
Printer Friendly Version
02/24/11Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today that management will present at three upcoming investor conferences. Citi Global Healthcare Conference Clay B. Siegall, Ph.D. President and Chief Executive Officer, will present a company overview on Tuesday, March 1, 2011, at 3:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com in the Investors and News se... 
Printer Friendly Version
02/08/11Seattle Genetics Reports Fourth Quarter and Year 2010 Financial Results
-Company on track for brentuximab vedotin BLA submission in first quarter of 2011- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash., Feb 08, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2010. The company also highlighted recent product development activities and upcoming milestones and provided its 2011 financial outlook. "The strong brentuximab vedoti... 
Printer Friendly Version
02/03/11Seattle Genetics Announces Exercise of Over-Allotment Option
BOTHELL, Wash., Feb 03, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,500,000 shares of common stock. Gross proceeds from the offering of an aggregate of 11,500,000 shares at a price to the public of $15.50 per share, before underwriting discounts and commissions and other offering ... 
Printer Friendly Version
02/02/11Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2010 Financial Results on February 8, 2011
BOTHELL, Wash., Feb 02, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2010 financial results on Tuesday, February 8, 2011, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on ... 
Printer Friendly Version
02/02/11Seattle Genetics Prices Public Offering of Common Stock
BOTHELL, Wash., Feb 02, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $15.50 per share. The gross proceeds to Seattle Genetics from this offering are expected to be $155,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Seattle Genetics. Se... 
Printer Friendly Version
02/01/11Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash., Feb 01, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Seattle Genetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferie... 
Printer Friendly Version
01/06/11Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Pfizer
- Seattle Genetics to receive $8 million upfront payment, over $200 million in potential milestone payments plus royalties under single-target collaboration - BOTHELL, Wash., Jan 06, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugat... 
Printer Friendly Version
01/04/11Seattle Genetics Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
BOTHELL, Wash., Jan 04, 2011 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011, at 9:30 a.m. Pacific Time / 12:30 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, ... 
Printer Friendly Version
12/13/10Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST
BOTHELL, Wash., Dec 13, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that management will present at the 2010 Deutsche Bank BioFEST conference on Tuesday, December 14, 2010, at 1:05 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investors and News" section. About Seattle Genetics Seattle Genetics is a clinical-stage biotechnol... 
Printer Friendly Version
12/07/10Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual Meeting
-97 Percent of Patients Had Reductions in Tumor Volume- -53 Percent of Patients Achieved Complete Remission- -BLA Submission for Relapsed or Refractory Hodgkin Lymphoma and ALCL Planned in First Quarter of 2011; Planned MAA Submission in First Half of 2011 Under Discussion with European Regulators- ORLANDO, Fla., Dec 07, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharma... 
Printer Friendly Version
12/05/10Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
-94 Percent of Patients Had Reductions in Tumor Volume- -34 Percent of Patients Achieved Complete Remission- -BLA Submission for Relapsed or Refractory Hodgkin Lymphoma and ALCL Planned in First Quarter of 2011; Planned MAA Submission in First Half of 2011 Under Discussion with European Regulators-   ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN - News) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit... 
Printer Friendly Version
11/30/10Seattle Genetics Announces Additions to Commercial Leadership Team
BOTHELL, Wash., Nov 30, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Chris Boerner, Ph.D. as Vice President, Marketing and Darren Cline as Vice President, Managed Markets. These appointments reflect the company's continuing preparations for the planned commercialization of brentuximab vedotin (SGN-35). Seattle Genetics expects to submit a Biologics License Application to the U.S. Food and Drug Administrati... 
Printer Friendly Version
11/29/10Seattle Genetics to Present at Piper Jaffray Health Care Conference
BOTHELL, Wash., Nov 29, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that its management will present a company overview at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 10:30 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investors and News" section. About Seattle Genetics Se... 
Printer Friendly Version
11/08/10Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at American Society of Hematology Annual Meeting
-Two Oral Presentations Highlight Brentuximab Vedotin in Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma- BOTHELL, Wash. & CAMBRIDGE, Mass., Nov 08, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd A... 
Printer Friendly Version
11/03/10Data from Brentuximab Vedotin (SGN-35) Phase I Clinical Trial Published in New England Journal of Medicine
BOTHELL, Wash. & CAMBRIDGE, Mass., Nov 03, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine. The trial was designed to assess the sa... 
Printer Friendly Version
11/01/10Seattle Genetics Reports Third Quarter 2010 Financial Results
Positive top-line data reported from pivotal Hodgkin lymphoma and phase II ALCL brentuximab vedotin trials position company for first half 2011 BLA submission Conference call today at 5:00 p.m. ET BOTHELL, Wash., Nov 01, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2010. The company also highlighted recent product development activities and upcomin... 
Printer Friendly Version
10/29/10Seattle Genetics to Present at Oppenheimer Healthcare Conference
BOTHELL, Wash., Oct 29, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that its management will present a company overview at the Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010, at 1:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investors and News" section. About Seattle Genetics Seattle... 
Printer Friendly Version
10/25/10Seattle Genetics and Millennium to Highlight Brentuximab Vedotin (SGN-35) at the International Symposium on Hodgkin Lymphoma
Three Presentations Highlighting SGN-35 in CD30-Positive Hematologic Malignancies COLOGNE, Germany, Oct 25, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being... 
Printer Friendly Version
10/20/10Agensys, an Affiliate of Astellas, and Seattle Genetics Announce Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer
SANTA MONICA, Calif. & BOTHELL, Wash., Oct 20, 2010 (BUSINESS WIRE) --Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid... 
Printer Friendly Version
10/19/10Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2010 Financial Results on November 1, 2010
BOTHELL, Wash., Oct 19, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2010 financial results on Monday, November 1, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Monday, No... 
Printer Friendly Version
10/11/10Seattle Genetics Reports Preliminary Data from Phase I Clinical Trial of SGN-75
SEATTLE, Oct 11, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing. SGN-75 is an antibody-drug conjugate (ADC) targeted to CD70. The data were presented ... 
Printer Friendly Version
10/11/10Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or Refractory ALCL
-Objective Responses Achieved in 86 Percent of Patients- - Phase II ALCL and Pivotal Hodgkin Lymphoma Brentuximab Vedotin Oral Presentations Scheduled at ASH Annual Meeting in December- BOTHELL, Wash. & CAMBRIDGE, Mass., Oct 11, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced positive top-line resu... 
Printer Friendly Version
10/04/10Seattle Genetics to Present SGN-75 Clinical Data at the European Society for Medical Oncology (ESMO) Congress
BOTHELL, Wash., Oct 04, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that preliminary data from a phase I study of SGN-75 in relapsed and refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma will be presented during a poster session at the 35th European Society for Medical Oncology (ESMO) Congress being held October 8-12, 2010 in Milan, Italy. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that ... 
Printer Friendly Version
09/27/10Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma
-Objective Responses Achieved in 75 percent of Patients; Median Duration of Response Greater than Six Months- -BLA Submission Planned in First Half of 2011- -Seattle Genetics to Host Conference Call and Webcast Today at 8:30 a.m. ET- BOTHELL, Wash. & CAMBRIDGE, Mass., Sep 27, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502... 
Printer Friendly Version
09/24/10Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal Hodgkin Lymphoma Clinical Trial
SEATTLE, Sep 24, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its management will host a conference call and webcast on Monday, September 27, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) regarding top-line results from its brentuximab vedotin (SGN-35) pivotal clinical trial in Hodgkin lymphoma. The live event will be available from Seattle Genetics' website at www.seattlegenetics.com, under th... 
Printer Friendly Version
09/14/10Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration
Copenhagen, Denmark and Bothell, WA; September 14, 2010 – Genmab A/S (OMX: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize Seattle Genetics’ ADC technology with its HuMax-TF antibody targeting the Tissue Factor antigen, which is expressed on numerous types of solid tumors. Seattle Genetics received an undisclosed upfront payment ... 
Printer Friendly Version
09/13/10Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint
Company to Discontinue Lintuzumab Development Program to Focus on Robust Pipeline Top-line Data to be Reported from Two Brentuximab Vedotin (SGN-35) Trials Within Next Six Weeks Conference Call to be Held Today at 8:30 a.m. ET BOTHELL, Wash., Sep 13, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary en... 
Printer Friendly Version
09/10/10Seattle Genetics to Host Conference Call and Webcast on September 13, 2010 to Discuss Top-line Data from Lintuzumab (SGN-33) Phase IIb Clinical Trial
SEATTLE, Sep 10, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its management will host a conference call and webcast on Monday, September 13, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) to discuss top-line results from its lintuzumab (SGN-33) phase IIb clinical trial in acute myeloid leukemia (AML). The live event will be available from Seattle Genetics' website at www.seattlegenetics.com, und... 
Printer Friendly Version
09/07/10Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences
BOTHELL, Wash., Sep 07, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that Seattle Genetics' management will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section. Morgan Stanley Global Healthcare Unplugged Conference ... 
Printer Friendly Version
09/02/10Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas
BOTHELL, Wash., Sep 02, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology. "This trial initiation increases the t... 
Printer Friendly Version
08/04/10Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference
BOTHELL, Wash., Aug 04, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will speak at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010, at 9:30 a.m. Eastern Time. A webcast of the presentation will be available from Seattle Genetics' website, http://www.seattlegenetics.com, under the "Investor and News" section. About Seattle Genetics Seattle Genetics is a clinical-stage biotechnology co... 
Printer Friendly Version
08/03/10Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech
Seattle Genetics to Receive $12 Million Upfront Payment, Over $900 Million in Potential Fees and Milestone Payments and Mid-Single Digit Royalties BOTHELL, Wash., Aug 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY). Under the expanded agreement, Genentech will pay an upfront fee of $12 million f... 
Printer Friendly Version
07/27/10Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline Progress
Top-Line Data from Two Late-Stage Clinical Programs Anticipated During 2010; Strong Financial Position Driving Progress Across Broad Product Pipeline Conference Call Today at 5:00 p.m. ET BOTHELL, Wash., Jul 27, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2010. The company also highlighted recent product development activities and upcoming milestones. "We had a strong second quarter ... 
Printer Friendly Version
07/20/10Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer
BOTHELL, Wash., Jul 20, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. "There is significant need for new pancreatic cancer therapies, demonstrated by the fact t... 
Printer Friendly Version
07/19/10Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2010 Financial Results on July 27, 2010
BOTHELL, Wash., Jul 19, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2010 financial results on Tuesday, July 27, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, July 27, 2010 2:00 p.m. Pacific Time (PT)... 
Printer Friendly Version
06/05/10Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma
Objective Responses and Tolerability Demonstrated in Retreatment Setting CHICAGO, Jun 05, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achiev... 
Printer Friendly Version
06/02/10Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences
BOTHELL, Wash., Jun 02, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section. Jefferies 2010 Global Life Sciences Conference Tuesday, June 8, 2010 1:00 p.m. Eastern Time Ne... 
Printer Friendly Version
05/24/10Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial
Preliminary Data Anticipated in Second Half of 2010 BOTHELL, Wash. & CAMBRIDGE, Mass., May 24, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin i... 
Printer Friendly Version
05/24/10Seattle Genetics Names Vice President, Sales and Announces Management Promotion
BOTHELL, Wash., May 24, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Charles (Chip) R. Romp as Vice President, Sales. Mr. Romp brings more than 19 years of biotechnology and pharmaceutical sales and sales management experience to the company, most recently from Genentech, a wholly owned member of the Roche Group. In addition, the company announced the promotion of Jonathan Drachman, M.D., to Senior Vice President, Research and Translational Medic... 
Printer Friendly Version
05/21/10Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at the American Society of Clinical Oncology Annual Meeting
BOTHELL, Wash., May 21, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois. The presentation will highlight data from Hodgkin lymphoma and systemic anapl... 
Printer Friendly Version
04/28/10Seattle Genetics to Present at Upcoming Investor Conferences
SEATTLE, Apr 28, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that management will present at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section. Deutsche Bank Securities 35th Annual Health Care Conference Eric L. Dobmeier, Chief Business Officer, will present a company overview on Wednesday, May 5, 2010, at 10:40 a.m.... 
Printer Friendly Version
04/27/10Seattle Genetics Reports First Quarter 2010 Financial Results
Company in Strong Financial Position; Focused on Key Data in Remainder of Year and Continued Advancement of Its Broad Product Pipeline Conference Call Today at 5:00 P.M. ET BOTHELL, Wash., Apr 27, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones. "We ended the first quarter in a strong financial position, and ... 
Printer Friendly Version
04/21/10Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR
ASG-5ME Expected to Advance into Phase I Clinical Trials During 2010 for Prostate and Pancreatic Cancers BOTHELL, Wash. & SANTA MONICA, Calif., Apr 21, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cance... 
Printer Friendly Version
04/21/10Seattle Genetics Highlights ADC and SEA Technologies at AACR
BOTHELL, Wash., Apr 21, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that research related to its antibody-drug conjugate (ADC) and sugar engineered antibody (SEA) technologies were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. The presentations demonstrate the mechanism of action of SGN-75, an ADC, in preclinical models and describe a novel approach for efficient, large-scale screening o... 
Printer Friendly Version
04/20/10Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2010 Financial Results on April 27, 2010
BOTHELL, Wash., Apr 20, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2010 financial results on Tuesday, April 27, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, April 27, 2010, 2:00 p.m. Pacific Time (PT) / ... 
Printer Friendly Version
04/20/10Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration
BOTHELL, Wash., Apr 20, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targe... 
Printer Friendly Version
04/08/10Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma
AETHERA Trial Designed to Support Full Approval in the United States and Europe Data from Ongoing Pivotal Trial to Be Reported in Second Half of 2010 and Provide Basis for NDA and MAA Submissions in the First Half of 2011 BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan, Apr 08, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (NASDAQ:SGEN), Takeda Pharmaceutical Company Limited (TOKYO:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the ... 
Printer Friendly Version
03/12/10Seattle Genetics to Present at Upcoming Investor Conferences
SEATTLE, Mar 12, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that management will present at two upcoming investor conferences. WBBA Life Science Innovation Northwest Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview on Tuesday, March 16, 2010, at 2:35 p.m. Pacific Time. Dr. Siegall will also participate on a panel, "From IP to IPO: The Journey to Initial Public Offering," on the same date at 4:00 p.m. Pacific Time.... 
Printer Friendly Version
03/11/10Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio
- Issued U.S. Patent Extends Patent Protection for Brentuximab Vedotin (SGN-35) to at Least 2025 - BOTHELL, Wash., Mar 11, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin (SGN... 
Printer Friendly Version
03/03/10Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech
BOTHELL, Wash., Mar 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). The milestone was triggered by Genentech's submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for an ADC utilizing Seattle Genetics' technology for the treatmen... 
Printer Friendly Version
02/25/10Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash., Feb 25, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "Investors and News" section. RBC Capital Markets Healthcare Conference Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present on a panel, "Building a Proprietary and Partnered ... 
Printer Friendly Version
02/09/10Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook
-More than $120 million generated during 2009 from collaboration activities--Conference call today at 5:00 p.m. ET-BOTHELL, Wash., Feb 09, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2009. The company also highlighted recent product development activities and planned milestones and provided its 2010 financial outlook. "In 2009 we made significant progress with our product pipeline, signed a str... 
Printer Friendly Version
02/03/10Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
BOTHELL, Wash., Feb 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refracto... 
Printer Friendly Version
02/02/10Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010
BOTHELL, Wash., Feb 02, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it will report its fourth quarter and year 2009 financial results on Tuesday, February 9, 2010, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, February 9, 2010, 2:00 p.m. Paci... 
Printer Friendly Version
01/05/10Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash., Jan 05, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010, at 11:00 a.m. Pacific Time. A live webcast of the presentation will be available from Seattle Genetics' website, www.seattlegenetics.com, under the "Investor and News" section. The conference is being held at the Westin St. Francis Hotel... 
Printer Friendly Version
12/21/09Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline
Seattle Genetics to Receive $12 Million Upfront Payment, up to $390 Million in Potential Milestone Payments and Mid-Single Digit RoyaltiesBOTHELL, Wash., Dec 21, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK. "... 
Printer Friendly Version
12/15/09Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
Seattle Genetics to Receive $60 Million Upfront Payment and Retain Full Commercialization Rights to Brentuximab Vedotin in U.S. and Canada; Takeda Group to Commercialize in the Rest of the WorldSeattle Genetics to Host Conference Call December 15, 2009 at 8:30 A.M. Eastern TimeBOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan, Dec 15, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceuti... 
Printer Friendly Version
12/14/09Seattle Genetics to Host Conference Call on December 15, 2009, to Discuss Brentuximab Vedotin (SGN-35) Partnering
SEATTLE, Dec 14, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN), today announced that its management will host a teleconference at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) on Tuesday, December 15, 2009, to discuss brentuximab vedotin (SGN-35) partnering. A press release with respect to brentuximab vedotin partnering will be issued prior to the teleconference. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeting CD30 that is in clinical trials for the t... 
Printer Friendly Version
12/11/09Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40)
SEATTLE--(BUSINESS WIRE)--Dec. 11, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported that it has been notified by Genentech, a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma... 
Printer Friendly Version
12/10/09Seattle Genetics to Present at 2009 Deutsche Bank Biotech Confab
BOTHELL, Wash., Dec 10, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 DB-Biotech Boston Confab on Tuesday, December 15, 2009, at 2:35 p.m. Eastern Time. The conference is being held at the Four Seasons Hotel in Boston, MA. The presentation will be webcast live and available for replay from Seattle Genetics' website, www.seattlegeneti... 
Printer Friendly Version
12/07/09Seattle Genetics Reports Data from Dacetuzumab Phase Ib Combination Clinical Trials
SEATTLE, Dec 07, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan(R) (rituximab) and Gemzar(R) (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid(R) (lenalidomide) for multiple myeloma. In addition, data were reported describing a diagnostic gene signature that may identify lymphoma patients who ... 
Printer Friendly Version
12/07/09Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma
-65 percent of patients who received weekly brentuximab vedotin doses of 0.8 mg/kg and higher achieved an objective response-SEATTLE, Dec 07, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I weekly-dosing clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), including multiple complete and partial remissions in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL). The da... 
Printer Friendly Version
12/01/09Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and Exposition
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 1, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana. A summary of the company’s ASH presentations is below and full abstracts can be accessed at the ASH website at... 
Printer Friendly Version
11/23/09Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration
BOTHELL, Wash. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Nov. 23, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at ... 
Printer Friendly Version
11/16/09Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology. “Our compelling preclinical data demonstrate that SGN-75 possesses potent antitumor... 
Printer Friendly Version
10/27/09Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 27, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the "Investors and News" section. Oppenheimer 20th Annual Healthcare Conference Todd E. Simpson, Chief Financial Officer, will present ... 
Printer Friendly Version
10/22/09Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results
-Brentuximab vedotin advancing towards planned U.S. product launch in 2011- -Conference call today at 5:00 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 22, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress. “We achieved several significant milestones during the thi... 
Printer Friendly Version
10/15/09Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2009 Financial Results on October 22, 2009
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 15, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2009 financial results on Thursday, October 22, 2009, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE a... 
Printer Friendly Version
10/13/09Seattle Genetics Names Head of Commercial and Announces Management Promotion
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 13, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Bruce J. Seeley as Executive Vice President, Commercial. Mr. Seeley brings more than 18 years of experience in oncology drug marketing and sales to the company, most recently from Genentech BioOncology. In addition, the company announced the promotion of Kirk D. Schumacher to Vice President, Legal Affairs and Compliance, and Gener... 
Printer Friendly Version
10/05/09Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial
-Phase Ib studies in non-Hodgkin lymphoma and multiple myeloma continue under worldwide collaboration with Genentech- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 5, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as c... 
Printer Friendly Version
09/29/09Seattle Genetics to Present at JMP Securities Healthcare Focus Conference
BOTHELL, Wash., Sep 29, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that company management will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Monday, October 5, 2009, at 8:30 a.m. Eastern Time. The conference is being held at The New York Palace Hotel in New York City. A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.co... 
Printer Friendly Version
09/22/09Seattle Genetics Introduces Novel Technology for Empowering Antibodies
BOTHELL, Wash., Sep 22, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC. "We are committed to pla... 
Printer Friendly Version
09/17/09Seattle Genetics to Present at UBS Global Life Sciences Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 17, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 UBS Global Life Sciences Conference on Tuesday, September 22, 2009, at 2:00 p.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York City. A webcast of the presentation will be available live and for replay from the ... 
Printer Friendly Version
09/08/09Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma
BOTHELL, Wash., Sep 08, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer's submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors. "We are pleased with the continued progress by... 
Printer Friendly Version
09/03/09Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Sep. 3, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will present at the following investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the "Investors and News" section. Thomas Weisel Partners 2009 Healthcare Conference Todd E. Simpson, Chief Financial Officer, will pre... 
Printer Friendly Version
08/24/09Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin Lymphoma
- Accrual Completed Six Months Ahead of Schedule - BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 24, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology. “Strong inte... 
Printer Friendly Version
08/13/09Seattle Genetics Announces Exercise of Over-Allotment Option
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 13, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,650,000 shares of common stock. Gross proceeds from the offering of an aggregate of 12,650,000 shares at a price to the public of $10.75 per share, before underwriting discounts and commissions and other o... 
Printer Friendly Version
08/11/09Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 11, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $10.75 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $118.2 million. The offering is expected to close on or about ... 
Printer Friendly Version
08/10/09Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 10, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Seattle Genetics also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock to co... 
Printer Friendly Version
08/10/09Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 10, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors. “With multiple product candidates using our ... 
Printer Friendly Version
07/24/09Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 24, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). This trial is designed to evaluate tolerability and activity when retreating patients who relapse after previously achieving an ob... 
Printer Friendly Version
07/23/09Seattle Genetics Reports Strong Pipeline Progress and Second Quarter 2009 Financial Results
Company expects to complete enrollment in pivotal trial of brentuximab vedotin (SGN-35) during the third quarter of 2009 Conference call today at 5:00 p.m. ET BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 23, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2009. The company also highlighted recent product development progress. “The second quarter featured strong clinical data ... 
Printer Friendly Version
07/17/09Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009
BOTHELL, Wash.--(BUSINESS WIRE)--Jul. 17, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2009 financial results on Thursday, July 23, 2009, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE ac... 
Printer Friendly Version
06/18/09Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 18, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN), today announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs. “We have observed promi... 
Printer Friendly Version
06/08/09Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma
Data Show Longer Duration of Responses and Concordance between Investigator-Assessed and Independent Review of Responses BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 8, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I clinical trial of SGN-35 administered every three weeks to patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. Data highlights include longer median duration of response than previously rep... 
Printer Friendly Version
06/08/09Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data
Multiple Single-Agent Responses in Patients with AML BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 8, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported multiple objective responses at well-tolerated doses from a phase I clinical trial of lintuzumab (SGN-33) in patients with acute myeloid leukemia (AML). The data were presented at the 14th Congress of the European Hematology Association (EHA) being held in Berlin, Germany. Lintuzumab is a humanized ... 
Printer Friendly Version
06/04/09Seattle Genetics to Present at the Needham Life Sciences Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 4, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Todd E. Simpson, Chief Financial Officer, will speak at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10, 2009, at 11:00 a.m. Eastern Time. A live webcast of the presentation will be available from Seattle Genetics’ website, www.seattlegenetics.com, under the “News and Investor Information” section. The conference is b... 
Printer Friendly Version
06/01/09Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
-At Doses of 0.8 mg/kg and Higher, 60 Percent of Patients Achieved Objective Responses- SEATTLE--(BUSINESS WIRE)--Jun. 1, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from an ongoing phase I weekly-dosing clinical trial of SGN-35, an antibody-drug conjugate (ADC), including multiple complete and partial responses in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL). The data are being... 
Printer Friendly Version
05/21/09Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress
BOTHELL, Wash.--(BUSINESS WIRE)--May. 21, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that data from a phase I clinical trial evaluating every three week dosing of SGN-35 and a phase I clinical trial of lintuzumab (SGN-33) will be reported at the 14th Congress of the European Hematology Association (EHA) being held June 4-7, 2009 in Berlin, Germany. The abstracts are available from the EHA website at www.ehaweb.org. “In... 
Printer Friendly Version
05/14/09Seattle Genetics Announces SGN-35 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting
BOTHELL, Wash., May 14, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that data from a phase I clinical trial evaluating weekly dosing of SGN-35 will be reported during an oral presentation at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting being held May 29 to June 2, 2009 in Orlando, Florida. The abstract, titled "Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) ... 
Printer Friendly Version
05/08/09Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May. 8, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will participate in the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “News and Investor Information” section. Bank of America and Merrill Lynch 2009 Health Care Conference Clay B. Siegal... 
Printer Friendly Version
04/23/09Seattle Genetics Reports Product Development Progress and First Quarter 2009 Financial Results
ADVANCES ACROSS CLINICAL PIPELINE OF CANCER DRUGS HIGHLIGHTED BY INITIATION OF SGN-35 PIVOTAL TRIAL BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 23, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter ended March 31, 2009. The company also highlighted recent product development progress. “We have started 2009 with substantial momentum, achieving multiple goals across our product pipeline and continuing to dri... 
Printer Friendly Version
04/22/09Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 22, 2009-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-t... 
Printer Friendly Version
04/21/09Seattle Genetics Highlights Dacetuzumab Preclinical Research at AACR
BOTHELL, Wash., Apr 21, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced preclinical data with dacetuzumab describing a diagnostic gene signature that may identify lymphoma patients who are more likely to respond to dacetuzumab therapy. In addition, data demonstrating the enhanced activity of dacetuzumab in combination with conventional chemotherapy agents were reported. The data were presented at the 2009 Annual Meeting of the ... 
Printer Friendly Version
04/16/09Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2009 Financial Results on April 23, 2009
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 16, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2009 financial results on Thursday, April 23, 2009, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE acc... 
Printer Friendly Version
04/07/09Seattle Genetics Announces Management Team Addition and Promotion to Support SGN-35 Commercialization Initiatives
COMPANY ALSO RECOGNIZES DR. PETER SENTER AS DISTINGUISHED FELLOW BOTHELL, Wash., Apr 07, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Vaughn B. Himes, Ph.D., as Executive Vice President, Technical Operations and the promotion of Morris Z. Rosenberg, D.Sc., to Executive Vice President, Process Sciences. In addition, the company has recognized Peter D. Senter, Ph.D., Vice President, Chemistry, as the comp... 
Printer Friendly Version
04/06/09Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Millennium
BOTHELL, Wash., Apr 06, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a worldwide collaboration agreement with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TOKYO:4502), for the development of antibody-drug conjugates (ADCs). Under the terms of the collaboration, Millennium will pay a $4 million upfront fee for an exclusive ADC license to... 
Printer Friendly Version
03/30/09Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 30, 2009-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to SGN-35 for the treatment of Hodgkin lymphoma. SGN-35, an antibody-drug conjugate (ADC), is in an ongoing pivotal trial under a Special Protocol Assessment (SPA) from the FDA for relapsed or refractory Hodgkin lymphoma. “Receiving fast track designati... 
Printer Friendly Version
03/24/09Seattle Genetics to Present at the Needham Cancer Therapeutics Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 24, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer, will speak at the Needham & Company Cancer Therapeutics: Today and Tomorrow conference on Thursday, March 26, 2009 at 9:20 a.m. Eastern time. A live webcast of the presentation will be available from Seattle Genetics’ website, www.seattlegenetics.com, under the “News and Investor Informatio... 
Printer Friendly Version
03/04/09Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 4, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it will participate in the following upcoming investor conferences. Barclays Capital Global Healthcare Conference Todd Simpson, Chief Financial Officer, will present on Wednesday, March 11, 2009, at 2:30 p.m. Eastern Time. The conference is being held at Loews Miami Beach Hotel in Miami Beach, FL. A webcast of the pres... 
Printer Friendly Version
02/25/09Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
DATA EXPECTED IN FIRST HALF OF 2010 BOTHELL, Wash., Feb 25, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has completed patient enrollment in a phase IIb clinical trial of lintuzumab (SGN-33) in combination with low-dose cytarabine chemotherapy for patients with acute myeloid leukemia (AML). "We are pleased to have achieved our enrollment goal of 210 patients in this global phase IIb trial in less than 18 months," said Th... 
Printer Friendly Version
02/19/09Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 19, 2009-- Seattle Genetics, Inc. (NASDAQ:SGEN), today announced that it has initiated a pivotal trial of SGN-35 for patients with relapsed or refractory Hodgkin lymphoma. The trial is being conducted under a Special Protocol Assessment (SPA), which is an agreement between the U.S. Food and Drug Administration (FDA) and Seattle Genetics regarding the trial design necessary to support an efficacy claim in a New Dr... 
Printer Friendly Version
02/05/09Seattle Genetics Reports Fourth Quarter and Year 2008 Financial Results and Provides 2009 Financial Outlook
SIGNIFICANT PROGRESS ACROSS PRODUCT PORTFOLIO HIGHLIGHTED BY PLANNED INITIATION OF SGN-35 PIVOTAL TRIAL IN HODGKIN LYMPHOMA IN EARLY 2009 BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2008. “Our 2008 accomplishments were marked by substantial progress across our product pipeline, in particular by successfully demonstrating the therapeutic ... 
Printer Friendly Version
01/29/09Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2008 Financial Results on February 5, 2009
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2008 financial results on Thursday, February 5, 2009, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
01/28/09Seattle Genetics Announces Pricing of Common Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the pricing of an underwritten public offering of 5,740,000 shares of its common stock. Upon closing, the aggregate price to the public will be approximately $55.8 million. UBS Investment Bank acted as sole manager for the offering. Seattle Genetics intends to use the net proceeds from this offering to fund research and development, including clinical trials and ... 
Printer Friendly Version
01/26/09Seattle Genetics Receives Orphan Drug Designations for SGN-35 in the United States and Europe
BOTHELL, Wash., Jan 26, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that SGN-35 has been granted orphan drug designation by the European Medicines Agency (EMEA) for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) and by the U.S. Food and Drug Administration (FDA) for the treatment of ALCL. These designations are in addition to the SGN-35 orphan drug designation for Hodgkin lymphoma previously rec... 
Printer Friendly Version
01/21/09Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin Lymphoma
INITIATION OF CLINICAL TRIALS FOR HODGKIN LYMPHOMA AND ALCL PLANNED IN FIRST QUARTER OF 2009 BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 21, 2009--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a pivotal trial of SGN-35, an antibody-drug conjugate (ADC), for patients with relapsed or refractory Hodgkin lymphoma. The SPA provides an agreemen... 
Printer Friendly Version
01/06/09Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2009--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2009, at 3:00 p.m. Pacific Time. A live webcast of the presentation will be available from Seattle Genetics' website, www.seattlegenetics.com, under the "News and Investor Information" section. The confere... 
Printer Friendly Version
12/10/08Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
STUDY ON TRACK TO COMPLETE ENROLLMENT IN MID-2009 AND REPORT DATA IN FIRST HALF OF 2010 BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 10, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that an Independent Data Monitoring Committee (IDMC) has completed a pre-specified safety review of data from the ongoing phase IIb trial of lintuzumab (SGN-33) in combination with low-dose cytarabine chemotherapy for older patients with acute myeloid leukemia (AML). After r... 
Printer Friendly Version
12/06/08Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma
AT DOSES OF 1.2 MG/KG AND HIGHER, 54 PERCENT OF EVALUABLE PATIENTS ACHIEVED OBJECTIVE RESPONSES AND 93 PERCENT HAD REDUCTIONS IN TUMOR VOLUME SEATTLE--(BUSINESS WIRE)--Dec. 6, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I clinical trial of SGN-35, an antibody-drug conjugate (ADC), demonstrating multiple complete and partial responses at well-tolerated doses in patients with relapsed or refractory Hodgkin lymphoma and other CD30-... 
Printer Friendly Version
12/06/08Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial
PRECLINICAL DATA DEMONSTRATE ENHANCED ACTIVITY OF DACETUZUMAB COMBINED WITH RITUXAN SEATTLE--(BUSINESS WIRE)--Dec. 6, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase II single-agent clinical trial of dacetuzumab (SGN-40) demonstrating objective responses at well-tolerated doses in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL), an aggressive type of non-Hodgkin lymphoma. Data were also presented from preclin... 
Printer Friendly Version
12/01/08Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash., Dec 01, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will participate in two upcoming investor conferences. Piper Jaffray 20th Annual Health Care Conference Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present on Wednesday, December 3, 2008 at 10:30 a.m. Eastern Time. A webcast of the presentation will be available live and for replay from Seattle Genetics' website,... 
Printer Friendly Version
10/29/08Seattle Genetics to Present at the Oppenheimer Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 29, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4, 2008, at 10:40 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under th... 
Printer Friendly Version
10/28/08Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 28, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody targeting CD70 that is in development as a novel therapy for autoimmune diseases. Seattle Genetics is currently conducting a phase I trial to assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy ... 
Printer Friendly Version
10/24/08Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 24, 2008--Seattle Genetics, Inc. (NASDAQ:SGEN), today announced data highlighting preclinical findings on two of its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-19A, as well as research advances with its proprietary ADC technology. The data are being presented at the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) International Conference on M... 
Printer Friendly Version
10/23/08Seattle Genetics Reports Development Progress and Third Quarter 2008 Financial Results
-- COMPANY ADVANCING BROAD PIPELINE OF CANCER THERAPIES AND PLANNING FOR PIVOTAL TRIALS OF SGN-35 IN 2009 -- -- CONFERENCE CALL TODAY AT 5:00 P.M. ET -- BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2008. "We are making strong progress across our product portfolio, including advancing twelve clinical trials of four product candidates and finalizing our SGN-35 regis... 
Printer Friendly Version
10/16/08Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2008 Financial Results on October 23, 2008
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it will report its third quarter 2008 financial results on Thursday, October 23, 2008, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, October 23, 2008, 2:00 p.m. Pacific T... 
Printer Friendly Version
10/15/08Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with Progenics
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with Progenics Pharmaceuticals (Nasdaq:PGNX). The milestone was triggered by Progenics' initiation of a phase I clinical trial with its prostate-specific membrane antigen (PSMA)-targeted ADC for patients with hormone-refractory prostate cancer. "This is the fourth product utilizing Seattle Genet... 
Printer Friendly Version
09/30/08Seattle Genetics Adds to Senior Management Team
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointments of Elaine Waller, PharmD to Senior Vice President, Regulatory Affairs and Christopher Pawlowicz to Senior Vice President, Human Resources, as well as the promotion of Jonathan Drachman, M.D. to Vice President, Early Clinical Development. "A strong senior management team is essential to the successful execution of our aggressive corporate goals, including moving SGN-35 into piv... 
Printer Friendly Version
09/17/08Seattle Genetics to Present at the UBS Global Life Sciences Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 17, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2008 UBS Global Life Sciences Conference on Tuesday, September 23, 2008, at 10:00 a.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York City. A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics... 
Printer Friendly Version
08/27/08Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 27, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics, will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Thomas Weisel Partners 2008 Healthcare Conference Wednesday, Septem... 
Printer Friendly Version
07/31/08Seattle Genetics Initiates SGN-70 Phase I Clinical Trial
BOTHELL, Wash.--(BUSINESS WIRE)--July 31, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial of SGN-70, a humanized monoclonal antibody targeting CD70 that is being developed as an investigational therapy for autoimmune diseases. The trial will assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers. "CD70 targeted therapies have shown promise in multiple preclinical models by reducing autoimmune d... 
Printer Friendly Version
07/22/08Seattle Genetics Reports Second Quarter 2008 Financial Results
-- CONFERENCE CALL TODAY AT 5:00 P.M. ET -- BOTHELL, Wash.--(BUSINESS WIRE)--July 22, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2008. "We made strong progress across our product pipeline during the second quarter, highlighted by positive data with SGN-35, an antibody-drug conjugate (ADC), presented at the American Society of Clinical Oncology (ASCO) annual meeting in June," said Clay B. Siegall... 
Printer Friendly Version
07/15/08Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2008 Financial Results on July 22, 2008
BOTHELL, Wash.--(BUSINESS WIRE)--July 15, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2008 financial results on Tuesday, July 22, 2008, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, July 22, 2008, 2:00 p.m. Pacific... 
Printer Friendly Version
07/08/08Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo
BOTHELL, Wash.--(BUSINESS WIRE)--July 8, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an exclusive, worldwide collaboration agreement with Daiichi Sankyo Co., Ltd. (TSE:4568) for the development of antibody-drug conjugates (ADCs) targeting a single antigen found on multiple types of solid tumors. Under the terms of the collaboration, Seattle Genetics will receive an upfront payment of $4 million, progress-dependent milestone payments and mid-... 
Printer Friendly Version
06/18/08Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing
BOTHELL, Wash.--(BUSINESS WIRE)--June 18, 2008--Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for an ADC utilizing Seattle Genetics' technology. "Genentech and our other collaborators continue to make strong progress wit... 
Printer Friendly Version
06/06/08Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma
SEATTLE--(BUSINESS WIRE)--June 6, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that SGN-35 will be highlighted in an oral presentation during a plenary session on Saturday, June 7, 2008 at the International Conference on Malignant Lymphoma (ICML) being held in Lugano, Switzerland. In a phase I dose-escalation trial of SGN-35, multiple patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies achieved objective responses, including five complete... 
Printer Friendly Version
06/05/08Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma
SEATTLE--(BUSINESS WIRE)--June 5, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced final data from the phase I clinical trial of SGN-40 in patients with relapsed or refractory non-Hodgkin lymphoma. SGN-40 is a humanized monoclonal antibody being developed under a worldwide collaboration agreement with Genentech, Inc. Multiple objective responses were achieved and SGN-40 was generally well tolerated with no maximum tolerated dose identified. The data were reported during an o... 
Printer Friendly Version
06/04/08Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--June 4, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Needham & Company 7th Annual Biotechnology and Medical Technology Conference Eric L. Dobmeier, Chief Business Officer, will present o... 
Printer Friendly Version
06/03/08Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma
-- 81% OF EVELUABLE PATIENTS ACHIEVED REDUCTIONS IN TUMOR VOLUME -- SEATTLE, Jun 03, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced positive data from a phase I clinical trial of SGN-35, an antibody-drug conjugate (ADC), demonstrating multiple objective responses at well-tolerated doses in patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. The data were presented during a poster discussion session at the American Society of C... 
Printer Friendly Version
06/02/08Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma
BOTHELL, Wash.--(BUSINESS WIRE)--June 2, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that its collaborator, Genentech, Inc., has initiated a phase Ib clinical trial of SGN-40 in combination with Velcade(R) (bortezomib) for patients with relapsed or refractory multiple myeloma. This is the sixth ongoing clinical trial to evaluate SGN-40 either as a single agent or in combination with standard therapies for non-Hodgkin lymphoma and multiple myeloma. "Recent approvals ... 
Printer Friendly Version
05/16/08Seattle Genetics Announces Upcoming SGN-35 Presentation at the American Society of Clinical Oncology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--May 16, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that SGN-35 phase I clinical data will be presented during a poster discussion session at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois. The abstract, titled "Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) t... 
Printer Friendly Version
05/06/08Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May 6, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Bank of America Healthcare Conference Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present on Tuesday, May 13, 2008 at ... 
Printer Friendly Version
04/24/08Seattle Genetics Reports First Quarter 2008 Financial Results
CONFERENCE CALL TODAT Y AT 5:00 P.M. ET BOTHELL, Wash., Apr 24, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the first quarter of 2008. "We continue to advance and expand our robust product pipeline, including recent trial initiations with each of our clinical programs, SGN-40, SGN-33 and SGN-35," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Also, we look forward to reporting additional data... 
Printer Friendly Version
04/17/08Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2008 Financial Results on April 24, 2008
BOTHELL, Wash., Apr 17, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2008 financial results on Thursday, April 24, 2008, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, April 24, 2008, 2:00 p.m. Pacific Time... 
Printer Friendly Version
04/15/08Seattle Genetics Presents Preclinical Data on its Antibody-Drug Conjugate Technology and SGN-33 Program at AACR
BOTHELL, Wash. & SAN DIEGO--(BUSINESS WIRE)--April 15, 2008--Seattle Genetics, Inc. (NASDAQ:SGEN) today announced data from multiple poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) highlighting preclinical findings with its proprietary antibody-drug conjugate (ADC) technology. Preclinical data were also presented on SGN-33, a humanized antibody that is in clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrom... 
Printer Friendly Version
04/09/08Seattle Genetics Highlights SGN-70 at AAI Annual Meeting
BOTHELL, Wash. & SAN DIEGO--(BUSINESS WIRE)--April 9, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) today presented data on SGN-70, a monoclonal antibody targeting CD70, demonstrating its potential for the treatment of autoimmune diseases at the American Association of Immunologists (AAI) annual meeting being held in San Diego, California. In addition, Seattle Genetics' anti-CD70 therapies were featured during the conference in an AAI Major Symposium entitled "TNF Family Members in Infla... 
Printer Friendly Version
04/08/08Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--April 8, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase Ib clinical trial of SGN-40 in combination with Rituxan(R) (rituximab) and Gemzar(R) (gemcitabine) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. "We are executing on a multi-pronged development plan with SGN-40 in DLBCL, an aggressive type of non-Hodgkin lymphoma, based on ... 
Printer Friendly Version
03/28/08Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial
STUDY TO EVALUATE MORE FREQUEST DOSING OF SGN-35, AS WELL AS COMBINATION WITH GEMZAR(R) BOTHELL, Wash.--(BUSINESS WIRE)--March 28, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a second phase I clinical trial of SGN-35 in patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent c... 
Printer Friendly Version
03/20/08Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS)
BOTHELL, Wash.--(BUSINESS WIRE)--March 20, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial to determine the safety profile and antitumor activity of SGN-33 (lintuzumab) in combination with the oral cancer drug Revlimid(R) (lenalidomide) for patients with intermediate and advanced myelodysplastic syndromes (MDS). The clinical trial is being conducted in collaboration with Celgene Corporation (Nasdaq: CELG) under a clinical resea... 
Printer Friendly Version
03/12/08Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--March 12, 2008--Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Cowen and Company 28th Annual Health Care Conference Eric Dobmeier, Chief Business Officer, will present on Tuesday, March 18, 2008, at 2:... 
Printer Friendly Version
02/08/08Seattle Genetics to Present at BIO CEO & Investor Conference
BOTHELL, Wash., Feb 08, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Biotechnology Industry Organization (BIO) CEO & Investor Conference on Wednesday, February 13, 2008, at 11:45 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. A webcast of the presentation will be available live and for replay from the Seattle Genetics websit... 
Printer Friendly Version
02/07/08Seattle Genetics Reports Fourth Quarter 2007 Financial Results and Provides 2008 Financial Outlook
-- CONFERENCE CALL TODAY AT 5:00 P.M. ET -- BOTHELL, Wash., Feb 07, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2007 and provided its 2008 financial outlook. "We made outstanding progress in 2007, including entering into an SGN-40 product collaboration with Genentech, reporting complete remissions with SGN-33 in AML and reporting objective responses with SGN-35 in Hodgkin lymphoma," sai... 
Printer Friendly Version
01/31/08Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year End 2007 Financial Results on February 7, 2008
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 31, 2008--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year end 2007 financial results on Thursday, February 7, 2008, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update and 2008 financial outlook. Access to the event can be obtained as follows: LIVE acces... 
Printer Friendly Version
01/25/08Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 25, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section. Wachovia 2008 Healthcare Conference Eric Dobmeier, Chief Business Officer, will present on Wednesday, January 30, 2008, at 2:30 p.m. Eastern... 
Printer Friendly Version
01/24/08Seattle Genetics Announces Completion of Common Stock Offering, Including Exercise of Over-Allotment Option
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 24, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the completion of its public offering of 11,500,000 shares of common stock, which includes exercise by the underwriters of their over-allotment option to purchase 1,500,000 shares. The public offering price of $9.00 per share results in net proceeds to Seattle Genetics of approximately $97.5 million, after deducting underwriting discounts and commissions and offering expenses. Sea... 
Printer Friendly Version
01/18/08Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 18, 2008--Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has agreed to sell an aggregate of 10,000,000 shares of its common stock in an underwritten public offering at a price to the public of $9.00 per share. The company has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any. All of the shares are being offered by Seattle Genetics. The offering ... 
Printer Friendly Version
01/14/08Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 14, 2008--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it intends to offer to sell, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock to cover over-allotments. All of the shares are being offered by the company. J.P. Morgan Securities Inc.... 
Printer Friendly Version
01/07/08Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 7, 2008--Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it will receive a $4 million milestone payment from its collaborator Genentech, Inc. The milestone payment has been triggered by Genentech's initiation of a phase Ib clinical trial of SGN-40 in combination with Rituxan(R) (rituximab) for patients with relapsed follicular or marginal zone non-Hodgkin lymphoma. "Preclinical data suggest that the combination of SGN-40 and Rituxa... 
Printer Friendly Version
01/04/08Seattle Genetics to Present at the 26th Annual JPMorgan Healthcare Conference
SEATTLE, Jan 04, 2008 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008, at 3:30 p.m. Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco, California. A live webcast of the presentation will be available from Seattle Genetics' website, www.seattlegenetics.com, under the "news... 
Printer Friendly Version
12/10/07Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH
Single-Agent Administration of SGN-33 Results in Seven Objective Responses Out of Seventeen AML Patients Treated in Phase Ia Dose-Escalation Clinical Trial SEATTLE--(BUSINESS WIRE)--Dec. 10, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive data from a phase Ia clinical trial of SGN-33 (lintuzumab) demonstrating multiple complete remissions at well-tolerated doses in patients with acute myeloid leukemia (AML). Preclinical data were a... 
Printer Friendly Version
12/07/07Seattle Genetics to Participate on Panel at RBC Capital Markets Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Dec. 7, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will participate in a panel entitled "Delivering on the Promise of Antibody Therapies for Cancer" on Wednesday, December 12, 2007 at 3:30 p.m. Eastern Time as part of the RBC Capital Markets 2007 Healthcare Conference being held at The Westin New York at Times Square Hotel in New York City. The panel discussion will be moderat... 
Printer Friendly Version
12/07/07Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Trial Initiation Triggers $12 Million Milestone Payment from Genentech BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 7, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase IIb clinical trial of SGN-40 in combination with Rituxan(R) (rituximab) plus chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Under the terms of the company's collaboration agreement with Genentech, Inc., Seattle Genetics will receive a $12... 
Printer Friendly Version
12/05/07Seattle Genetics to Host Research and Development Day on December 12, 2007
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 5, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that company management will host a research and development day for the financial community on December 12, 2007 beginning at 9:15 a.m. Eastern Time. The event will be held at the Grand Hyatt Hotel in New York City. The meeting will include a review of recent clinical data reported on SGN-33 and SGN-35 and a discussion of the company's SGN-40 clinical development program in collabo... 
Printer Friendly Version
11/09/07Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase IIb clinical trial of SGN-33 (lintuzumab), a monoclonal antibody, in combination with a low-dose regimen of the chemotherapeutic agent cytarabine for patients with acute myeloid leukemia (AML). The randomized, double-blind, placebo-controlled study is designed to assess whether this combination regimen extends survival compared to cytarabine alone in previo... 
Printer Friendly Version
11/05/07Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma
Tumor Reductions Achieved in More Than 75% of Patients, Including Four Partial Responses, Through Treatment by New Class of Antibody-Drug Conjugate BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 5, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced positive data from an ongoing phase I trial of SGN-35, a proprietary antibody-drug conjugate (ADC) product candidate. Multiple objective responses have been observed at well-tolerated doses of SGN-35 i... 
Printer Friendly Version
11/01/07Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma
-- Trial Initiation Triggers $4 Million Milestone Payment from Genentech -- BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 1, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase Ib clinical trial of SGN-40 in combination with Revlimid(R) (lenalidomide) and dexamethasone, a steroid, for patients with relapsed or refractory multiple myeloma. As a result, the company will receive a $4 million milestone payment from its collabor... 
Printer Friendly Version
10/31/07Seattle Genetics and MedImmune Expand Antibody-Drug Conjugate Collaboration
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 31, 2007--Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that MedImmune, Inc., has exercised its option to obtain an exclusive license to a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration, triggering a $1.5 million payment to Seattle Genetics. Seattle Genetics' ADC technology empowers antibodies by linking them to potent drug payloads. The company's technology employs synthetic, highly pote... 
Printer Friendly Version
10/30/07Seattle Genetics to Present at the CIBC World Markets Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 30, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will speak at the CIBC World Markets 18th Annual Healthcare Conference on Tuesday, November 6, 2007, at 9:45 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, unde... 
Printer Friendly Version
10/24/07Seattle Genetics Reports Preclinical Data on SGN-40 and an Anti-CD19 Antibody-Drug Conjugate
-- Company's ADC Collaborators Also Demonstrate Progress during AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 24, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported preclinical data on SGN-40, a humanized monoclonal antibody that is currently in clinical trials for non-Hodgkin's lymphoma and multiple myeloma in collaboration with Genentech, Inc. In addition, data ... 
Printer Friendly Version
10/23/07Seattle Genetics Reports Third Quarter 2007 Financial Results and Progress in Advancing Pipeline
-- Conference Call Today at 5:00 p.m. ET -- BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 23, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2007. "We are aggressively advancing our broad pipeline of antibody-based therapies for cancer by initiating multiple clinical trials of SGN-40, SGN-33 and SGN-35 over the next six months," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of ... 
Printer Friendly Version
10/16/07Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2007 Results on October 23, 2007
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 16, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2007 financial results on Tuesday, October 23, 2007, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, October 23, 2007, 2:00 p.m. P... 
Printer Friendly Version
09/06/07Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 6, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that management will present at four upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section, except as noted. Bear Stearns 20th Annual Healthcare Conference Tuesday, September 11, 2007, at 4:00 p.m. Eastern Time. The conference is ... 
Printer Friendly Version
07/25/07Seattle Genetics Reports Second Quarter 2007 Financial Results and Highlights Pipeline Progress
-- Company in Strong Financial Position to Continue Advancing Its Diverse Pipeline of Antibody-Based Product Candidates for Unmet Needs in Cancer -- -- Conference call today at 5:00 p.m. ET --BOTHELL, Wash., Jul 25, 2007 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2007. In addition, the company provided an update on its broad pipeline of antibody-based therapies for the treatment of unmet needs ... 
Printer Friendly Version
07/17/07Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on July 25, 2007
BOTHELL, Wash.--(BUSINESS WIRE)--July 17, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2007 financial results on Wednesday, July 25, 2007, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Wednesday, July 25, 2007, 2:00 p.m. Pac... 
Printer Friendly Version
06/14/07Seattle Genetics Adds Industry Veterans John P. McLaughlin and Daniel G. Welch to its Board of Directors and Promotes Eric Dobmeier to Chief Business Officer
BOTHELL, Wash., Jun 14, 2007 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that industry veterans John P. McLaughlin and Daniel G. Welch have joined its Board of Directors, together bringing over 50 years of commercial and operational leadership to the company. The company also announced that Eric L. Dobmeier has been promoted to the newly created position of Chief Business Officer. "John's and Dan's extensive experience and successful track records will provide ... 
Printer Friendly Version
05/25/07Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May 25, 2007--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. Bank of America 2007 Health Care Conference Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak on Thursday, May 31, 2007, a... 
Printer Friendly Version
04/24/07Seattle Genetics Reports First Quarter 2007 Financial Results and Corporate Accomplishments
Conference Call Today at 5:00 p.m. ET BOTHELL, Wash.--(BUSINESS WIRE)--April 24, 2007--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results and corporate accomplishments for the first quarter ended March 31, 2007. Revenues for the first quarter of 2007 increased to $4.3 million, from $2.1 million in the first quarter of 2006, primarily due to amounts earned under the company's SGN-40 collaboration with Genentech established in January 2007. In addition, revenu... 
Printer Friendly Version
04/17/07Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
Multiple Presentations Demonstrate Potential of Company's Leading ADC Technology Platform to Empower Antibodies for the Treatment of Cancer BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--April 17, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical advances with... 
Printer Friendly Version
04/17/07Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2007 Results on April 24, 2007
BOTHELL, Wash.--(BUSINESS WIRE)--April 17, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2007 financial results on Tuesday, April 24, 2007, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, April 24, 2007, 2:00 p.m. Pacif... 
Printer Friendly Version
04/10/07Seattle Genetics Announces Multiple Presentations at Upcoming American Association for Cancer Research Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--April 10, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that fifteen abstracts associated with the company's ADC technology, antibody-based therapeutics and collaborator programs will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 14-18, 2007, at the Los Angeles Convention Center, Los Angeles, CA. In addition, Peter D. Senter, Ph.D., Vice President, Chemistry at Seattle Genet... 
Printer Friendly Version
04/09/07Seattle Genetics to Present at the CIBC World Markets Biotechnology and Specialty Pharmaceuticals Conference
BOTHELL, Wash.--(BUSINESS WIRE)--April 9, 2007--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals conference on Thursday, April 12, 2007, at 10:20 a.m. Eastern Time. The conference is being held at the Millennium Broadway hotel in New York City. A webcast of the presentation will be available live and for replay from the Se... 
Printer Friendly Version
03/27/07Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
-- Seattle Genetics Receives $4.5 Million Payment from Genentech BOTHELL, Wash.--(BUSINESS WIRE)--March 27, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Genentech, Inc. has paid $4.5 million to exercise exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies... 
Printer Friendly Version
03/20/07Seattle Genetics Appoints Dr. Tom Reynolds Chief Medical Officer
BOTHELL, Wash.--(BUSINESS WIRE)--March 20, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Thomas C. Reynolds, M.D., Ph.D., has joined the company as Chief Medical Officer. In this role, Dr. Reynolds will oversee clinical and regulatory activities across the company's product portfolio focused on cancer and autoimmune disease. "Tom has more than 15 years of drug development expertise and a proven track record of building and leading clinical teams and programs," s... 
Printer Friendly Version
02/26/07Seattle Genetics to Present at the Susquehanna Financial Group Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 26, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Susquehanna Financial Group "SIGnificant Investment Options in Healthcare" conference on Thursday, March 1, 2007, at 4:00 p.m. Eastern Time. The conference is being held at the Omni Berkshire Place hotel in New York City. A webcast of the presentation will be available live and for replay from t... 
Printer Friendly Version
02/13/07Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 13, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SGN-33 for the treatment of acute myeloid leukemia (AML) and to SGN-35 for the treatment of Hodgkin's disease. "SGN-33 and SGN-35 both target diseases with significant unmet medical needs and represent opportunities for well-tolerated biologics that provide improved treatment options for patient... 
Printer Friendly Version
02/09/07Seattle Genetics to Present at the BIO CEO & Investor Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 9, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Biotechnology Industry Organization (BIO) CEO & Investor Conference on Tuesday, February 13, 2007, at 9:45 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. A webcast of the presentation will be available live and for replay from the Seattle Genetics we... 
Printer Friendly Version
02/06/07Seattle Genetics Reports Fourth Quarter and Year-End 2006 Results and Provides 2007 Financial Outlook
Strong Financial Position Enables Advancement of Multiple Product Candidates for Cancer Conference call today at 5:00 p.m. ET BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 6, 2007--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for its fourth quarter and year ended December 31, 2006 and provided 2007 financial guidance. Fourth Quarter and Year 2006 Financial Results Summary Revenues for the fourth quarter of ... 
Printer Friendly Version
01/30/07Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year End 2006 Results on February 6, 2007
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 30, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter 2006 financial results on Tuesday, February 6, 2007, after the close of U.S. financial markets. Following the announcement, company management will host a conference call to discuss the results and provide a general corporate update and 2007 financial guidance. Access to the event can be obtained as follows: LIVE access on Tuesday, February 6,... 
Printer Friendly Version
01/08/07Seattle Genetics to Present at the JPMorgan Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 8, 2007--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 25th Annual JPMorgan Healthcare Conference on Thursday, January 11, 2007, at 12:30 p.m. Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco, California. Dr. Siegall's presentation will provide an update on the company's programs, including the recently announced ... 
Printer Friendly Version
01/08/07Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
Seattle Genetics to Hold Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. & BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 8, 2007--Genentech (NYSE: DNA) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that they have entered into an exclusive worldwide license agreement for the development and commercialization of SGN-40. SGN-40 is a humanized monoclonal antibody currently in Phase I and Phase II clinical trials for multiple myeloma, chronic lymphocytic leukemia ... 
Printer Friendly Version
01/08/07Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
BOTHELL, Wash. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Jan. 8, 2007--Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., a private cancer biotechnology company, today announced an agreement to jointly research, develop and commercialize antibody-drug conjugate (ADC) therapies for cancer. The collaboration will encompass combinations of Seattle Genetics' ADC technology with antibodies developed by Agensys to proprietary cancer targets. Under the terms of the multi-year agreeme... 
Printer Friendly Version
12/20/06Seattle Genetics Initiates Phase II Clinical Trial of SGN-40 for the Treatment of Non-Hodgkin's Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 20, 2006--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the company has initiated a phase II clinical trial of SGN-40 for the treatment of patients with diffuse large B-cell lymphoma, the most common type of aggressive non-Hodgkin's lymphoma (NHL). Positive phase I data were reported last week at the American Society of Hematology annual meeting demonstrating that SGN-40 is well-tolerated and induces objective antitumor activity i... 
Printer Friendly Version
12/12/06Seattle Genetics Announces Advancements in Development Programs at American Society of Hematology Meeting
Eleven Presentations Highlight Breadth of Therapeutic Antibody Programs SEATTLE--(BUSINESS WIRE)--Dec. 12, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced clinical and preclinical data from the company's five lead antibody-based product candidates reported in multiple presentations during the American Society of Hematology (ASH) 48th Annual Meeting and Exposition in Orlando, Florida. "The data presented at ASH highlight the continued a... 
Printer Friendly Version
12/11/06Seattle Genetics Reports Positive Phase I Clinical Trial Results with SGN-40 in Non-Hodgkin's Lymphoma and Multiple Myeloma at ASH
Durable objective responses observed in relapsed/refractory NHL patients SEATTLE--(BUSINESS WIRE)--Dec. 11, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive data from a phase I trial of lead product candidate SGN-40, demonstrating that it exhibits durable objective responses and is well-tolerated in patients with non-Hodgkin's lymphoma (NHL) who have failed multiple prior therapies. Another phase I study showed SGN-40 induces antit... 
Printer Friendly Version
12/08/06Seattle Genetics to Participate on Panel at RBC Capital Markets Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Dec. 8, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will participate in a panel discussion entitled "Cancer Antibodies: Developing A Pipeline" on Wednesday, December 13, 2006, at 11:00 a.m. Eastern Time as part of the 2006 RBC Capital Markets Healthcare Conference being held at the Westin New York at Times Square Hotel in New York City. The panel will be moderated by Jason Kant... 
Printer Friendly Version
12/01/06Seattle Genetics Announces Upcoming Presentations at the American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 1, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that twelve abstracts related to the Company's clinical and preclinical development programs are scheduled for presentation and/or publication at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) being held December 9-12, 2006, at the Orange County Convention Center in Orlando, FL. SGN-40 -- SGN-40 (anti-huCD40 mAb) monotherapy induces durable obj... 
Printer Friendly Version
11/17/06Seattle Genetics Initiates Phase I Clinical Trial of SGN-35
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 17, 2006--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has initiated a phase I clinical trial of SGN-35 for patients with Hodgkin's disease and other CD30-positive hematologic malignancies. SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs. "SGN-35 represents an exciting, emerging class of antibody-based therapeut... 
Printer Friendly Version
11/02/06Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 2, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at two upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. The following is a schedule of the presentations: -- CIBC World Mark... 
Printer Friendly Version
10/24/06Seattle Genetics Reports Third Quarter 2006 Financial Results and Pipeline Progress
Business Editors BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 24, 2006--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for the third quarter and nine months ended September 30, 2006. "We are continuing to advance our diverse product pipeline, most notably by preparing to initiate in 2006 a phase II trial of SGN-40 in diffuse large B-cell lymphoma, a large market with a clear unmet medical need," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seat... 
Printer Friendly Version
10/17/06Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2006 Results on October 24, 2006
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 17, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2006 financial results on Tuesday, October 24, 2006, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, October 24, 2006, 2:00 p.m. Pa... 
Printer Friendly Version
10/12/06Seattle Genetics to Present at the BIO Investor Forum
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 12, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present in two sessions during the Biotechnology Industry Organization (BIO) Investor Forum taking place at the Palace Hotel in San Francisco. Dr. Siegall will provide a company update on Wednesday, October 18, at 10:40 a.m. Pacific Time. The presentation will be webcast live and available for replay from the Seat... 
Printer Friendly Version
09/21/06Seattle Genetics to Present at the UBS Global Life Sciences Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 21, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Wednesday, September 27, 2006, at 2:30 p.m. Eastern time. The conference is being held at the Grand Hyatt in New York. The presentation will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "ne... 
Printer Friendly Version
07/25/06Seattle Genetics Reports Second Quarter 2006 Financial Results and Pipeline Progress
BOTHELL, Wash.--(BUSINESS WIRE)--July 25, 2006-- Conference call today at 5:00 p.m. ET Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for the second quarter ended June 30, 2006. "During the quarter, we continued to advance our diverse pipeline of clinical-stage cancer therapies," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Most notably, we reported encouraging data demonstrating clinical activ... 
Printer Friendly Version
07/18/06Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2006 Results on July 25, 2006
BOTHELL, Wash.--(BUSINESS WIRE)--July 18, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2006 financial results on Tuesday, July 25, 2006, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Tuesday, July 25, 2006, 2:00 p.m. Pacific... 
Printer Friendly Version
07/06/06Seattle Genetics to Present at the C.E. Unterberg, Towbin Emerging Growth Conference
BOTHELL, Wash.--(BUSINESS WIRE)--July 6, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Senior Vice President, Corporate Development, will present at the C.E. Unterberg, Towbin Emerging Growth Conference on Tuesday, July 11, 2006, at 8:44 a.m. Pacific Time. The conference is being held at the Mandarin Oriental Hotel in New York. The presentation will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.c... 
Printer Friendly Version
06/22/06Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with CuraGen
BOTHELL, Wash.--(BUSINESS WIRE)--June 22, 2006--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with CuraGen Corporation (NASDAQ:CRGN), triggering an undisclosed payment to Seattle Genetics. The milestone was achieved upon CuraGen's initiation of a phase I clinical trial with its lead ADC, CR011-vcMMAE, for the treatment of metastatic melanoma. "ADCs have the potential to transfor... 
Printer Friendly Version
06/09/06Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash., Jun 09, 2006 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. Pacific Growth Equities 2006 Life Sciences Growth Conference Eric L. Dobmeier, Senior Vice President, Corporate Development, will speak on Tuesday, June 1... 
Printer Friendly Version
06/05/06Seattle Genetics Reports Encouraging SGN-40 Clinical Data at the American Society of Clinical Oncology Annual Meeting
Multiple Objective Responses Observed in Patients with Aggressive Non-Hodgkin's Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)--June 5, 2006-- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from its phase I clinical trial of SGN-40 in non-Hodgkin's lymphoma at the American Society of Clinical Oncology (ASCO) 42nd Annual Meeting being held in Atlanta June 2-6. SGN-40 induced objective responses in five patients and was well tolerated at doses up to 8 mill... 
Printer Friendly Version
05/25/06Seattle Genetics Announces Closing of Common Stock Sale
BOTHELL, Wash.--(BUSINESS WIRE)--May 25, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced closing of the sale of 1,129,015 shares of common stock to investment funds affiliated with Baker Brothers Investments (BBI) at a price of $5.25 per share, for proceeds of $5.9 million. This sale, which was subject to stockholder approval, was made pursuant to a stock purchase agreement between BBI and Seattle Genetics in connection with the company's public offering of common stock com... 
Printer Friendly Version
05/16/06Seattle Genetics Names Pamela Trail, Ph.D., as Chief Scientific Officer
BOTHELL, Wash.--(BUSINESS WIRE)--May 16, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Pamela A. Trail, Ph.D., a pharmaceutical industry veteran with almost 20 years of research and development experience, has joined the Company as its Chief Scientific Officer. Dr. Trail's career has focused on the discovery and preclinical development of monoclonal antibody-based cancer therapies. She joins Seattle Genetics from Bayer Healthcare where she spent more than five y... 
Printer Friendly Version
05/15/06Seattle Genetics to Present at the Bank of America Health Care Conference
BOTHELL, Wash.--(BUSINESS WIRE)--May 15, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Bank of America 2006 Health Care Conference on Thursday, May 18, 2006, at 10:00 a.m. Pacific Time. The conference is being held at the Four Seasons Hotel in Las Vegas. The presentation will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under ... 
Printer Friendly Version
05/04/06Seattle Genetics Reports on SGN-30 Cutaneous ALCL Phase II Clinical Trial at the Society of Investigative Dermatology Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--May 4, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from its ongoing phase II clinical trial of SGN-30 in cutaneous anaplastic large cell lymphoma (ALCL) and other lymphoproliferative disorders at the Society of Investigative Dermatology annual meeting being held in Philadelphia May 3-6. Multiple patients achieved objective antitumor responses to SGN-30 therapy, including both complete and partial responses. The study includes patient... 
Printer Friendly Version
04/25/06Seattle Genetics Reports First Quarter 2006 Financial Results
Management will host conference call today at 5:00 p.m. Eastern Time BOTHELL, Wash.--(BUSINESS WIRE)--April 25, 2006-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its first quarter ended March 31, 2006. Revenues for the first quarter of 2006 were $2.1 million, compared to $2.6 million in the first quarter of 2005. Revenues are generated from fees and milestones earned through the company's antibody-drug conjugate (ADC) technology collaborations. Total o... 
Printer Friendly Version
04/25/06Seattle Genetics and Laureate Pharma Announce Manufacturing Agreement
BOTHELL, Wash. & PRINCETON, N.J., Apr 25, 2006 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Laureate Pharma, Inc. announced today that they have entered into an agreement for manufacturing of Seattle Genetics' SGN-33 and SGN-70 humanized monoclonal antibody product candidates. Under the terms of the agreement, Laureate Pharma will perform scale-up and cGMP manufacturing of clinical trial materials for both programs. "These manufacturing campaigns are an important part of o... 
Printer Friendly Version
04/18/06Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2006 Results on April 25, 2006
BOTHELL, Wash.--(BUSINESS WIRE)--April 18, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2006 financial results on Tuesday, April 25, 2006, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows. LIVE access on Tuesday, April 25, 2006, 2:00 p.m. Pacif... 
Printer Friendly Version
04/11/06Seattle Genetics Receives Key Anti-CD30 Patent Claims
BOTHELL, Wash.--(BUSINESS WIRE)--April 11, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a patent entitled "Recombinant Anti-CD30 Antibodies and Uses Thereof." The issued claims cover methods of using certain anti-CD30 antibodies for the treatment of Hodgkin's disease, both as a single agent and in combination with other therapies. The company currently has two anti-CD30 product ca... 
Printer Friendly Version
04/10/06Seattle Genetics to Present at the BIO 2006 Convention
BOTHELL, Wash.--(BUSINESS WIRE)--April 10, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present in two sessions during the Biotechnology Industry Organization (BIO) 2006 Annual International Convention taking place at McCormick Place Convention Center in Chicago. Dr. Siegall will provide a company overview during the BIO Business Forum on Tuesday, April 11, at 9:15 a.m. Central Time in Room A, McCor... 
Printer Friendly Version
04/04/06Seattle Genetics Reports Continued Advances with SGN-70 and Its ADC Technology at the AACR Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--April 4, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it is reporting data on its SGN-70 program and proprietary antibody-drug conjugate (ADC) technology during six poster presentations at the 2006 Annual Meeting of the American Association for Cancer Research (AACR). The meeting is being held April 1-5, 2006, in Washington, DC. "We are pleased to report strong preclinical data at AACR on our SGN-70 product candidate, a humanized... 
Printer Friendly Version
04/03/06Seattle Genetics Announces Closing of Common Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)--April 3, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the closing of its public offering of 7,300,000 shares of common stock. Net proceeds to the company are approximately $37.2 million. Banc of America Securities LLC and CIBC World Markets Corp. acted as joint book-running managers for the offering. Seattle Genetics intends to use the net proceeds to fund clinical and preclinical development of its existing product candidates, manufactur... 
Printer Friendly Version
03/30/06Seattle Genetics Announces Proceeds of Common Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)--March 30, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the net proceeds to the company from its offering of 7,300,000 shares of common stock will be approximately $37.2 million. Banc of America Securities LLC and CIBC World Markets Corp. are acting as joint book-running managers for the offering. The company expects the closing of the offering to occur on or about April 3, 2006. Seattle Genetics intends to use the net proceeds from t... 
Printer Friendly Version
03/28/06Seattle Genetics Announces Common Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)--March 28, 2006--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it intends to issue and sell 7,300,000 shares of common stock in an underwritten public offering pursuant to an effective registration statement. Banc of America Securities LLC and CIBC World Markets will act as joint book-running managers for the offering. In addition, Seattle Genetics has agreed to sell 1,129,015 shares of common stock to investment funds affiliated with Ba... 
Printer Friendly Version
03/17/06Seattle Genetics to Present at Invest Northwest Conference
BOTHELL, Wash.--(BUSINESS WIRE)--March 17, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Invest Northwest CEO and Investor Forum on Tuesday, March 21, 2006, at 9:20 a.m. Pacific time. The conference is being held March 21-22 at the Bell Harbor International Conference Center in Seattle, Washington. The presentation will be webcast live and available for replay from the Seattle Gene... 
Printer Friendly Version
03/10/06Seattle Genetics Appoints Dr. Daniel Hoth to Board of Directors
BOTHELL, Wash., Mar 10, 2006 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Daniel F. Hoth, M.D., a clinical and drug development veteran with more than 25 years of experience, has been appointed to the company's Board of Directors. "Dan has significant knowledge in oncology drug development, regulatory affairs and clinical trial design and execution," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "His background an... 
Printer Friendly Version
02/08/06Seattle Genetics to Present at the BIO CEO and Investor Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 8, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Biotechnology Industry Organization (BIO) CEO and Investor Conference on Wednesday, February 15, 2006, at 12:00 p.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York. The presentation will be webcast and available both live and for replay via the company's website... 
Printer Friendly Version
02/07/06Seattle Genetics Reports Fourth Quarter and Year 2005 Financial Results
Management Will Host Conference Call Today at 5:00 P.M. Eastern TimeBOTHELL, Wash., Feb 07, 2006 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for its fourth quarter and year ended December 31, 2005. Revenues for the fourth quarter of 2005 were $2.3 million, compared to $1.7 million for the fourth quarter of 2004. For the year ended December 31, 2005, revenues increased to $9.8 million, compared to $6.7 million for the year ended December 31, 200... 
Printer Friendly Version
01/31/06Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2005 Results on February 7, 2006
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 31, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its fourth quarter and year 2005 financial results on Tuesday, February 7, 2006, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows. LIVE access on Tuesday, February 7, 2006, ... 
Printer Friendly Version
01/05/06Seattle Genetics to Present at the 24th Annual JPMorgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 5, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 24th Annual JPMorgan Healthcare Conference on Thursday, January 12, 2006, at 11:00 a.m. Pacific time. The conference is being held at the Westin St. Francis Hotel in San Francisco, California. A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www... 
Printer Friendly Version
12/13/05Seattle Genetics Reports Preclinical Data on its SGN-40 and SGN-70 Programs at the American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 13, 2005-- SGN-40 clinical data reported in prior meeting sessions Seattle Genetics, Inc. (Nasdaq:SGEN) reported preclinical data from its SGN-40 and SGN-70 programs at the American Society of Hematology (ASH) 2005 Annual Meeting being held in Atlanta December 10-13. Preclinical studies of SGN-40 demonstrated broad application in B-cell malignancies, including Hodgkin's disease and chronic lymphocytic leukemia, and in combinati... 
Printer Friendly Version
12/12/05Seattle Genetics Reports on SGN-30 Clinical Program at the American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 12, 2005-- Preclinical data on SGN-35 also presented Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from its ongoing clinical trials of SGN-30, an anti-CD30 monoclonal antibody, at the American Society of Hematology (ASH) 2005 Annual Meeting being held in Atlanta December 10-13. Data from these phase II clinical trials in systemic anaplastic large cell lymphoma (ALCL) and cutaneous ALCL demonstrate that SGN-30 i... 
Printer Friendly Version
12/12/05Seattle Genetics Reports SGN-40 Clinical Data at the American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 12, 2005-- Objective responses observed in ongoing phase I clinical trial of SGN-40 in non-Hodgkin's lymphoma Seattle Genetics, Inc. (Nasdaq: SGEN) reported data from its ongoing clinical trials of SGN-40 in multiple myeloma and non-Hodgkin's lymphoma at the American Society of Hematology (ASH) 2005 Annual Meeting being held in Atlanta December 10-13. Data from these phase I studies demonstrate that SGN-40 is well t... 
Printer Friendly Version
11/29/05Seattle Genetics Expands SGN-40 Clinical Program into Chronic Lymphocytic Leukemia
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 29, 2005-- SGN-40 granted FDA orphan drug designation in CLL Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I/II clinical trial of SGN-40 in patients with chronic lymphocytic leukemia (CLL). This is the company's third clinical indication for SGN-40, a humanized monoclonal antibody that targets the CD40 antigen. Seattle Genetics is also conducting ongoing phase I studies of SGN-40 in multipl... 
Printer Friendly Version
11/17/05Seattle Genetics Initiates SGN-33 Clinical Trial
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 17, 2005-- Company Now Conducting Clinical Development of Three Antibody Product Candidates Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial of SGN-33, a humanized anti-CD33 monoclonal antibody, for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study is designed to evaluate the safety, pharmacokinetic profile and antitum... 
Printer Friendly Version
11/14/05Seattle Genetics to Present on ADC Technology at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 14, 2005-- Two ADC Collaborators Also Scheduled to Report Preclinical Data Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it will report preclinical advances with its antibody-drug conjugate (ADC) technology during the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 14-18, 2005 at the Pennsylvania Convention Center in Philadelphia. In addition, two of Seattle G... 
Printer Friendly Version
11/03/05Seattle Genetics to Present at CIBC World Markets Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 3, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the CIBC World Markets 16th Annual Healthcare Conference on Tuesday, November 8, 2005, at 1:30 p.m. Eastern time. The conference is being held at the Waldorf-Astoria Hotel in New York. Dr. Siegall will provide an overview of key company programs as well as recent and planned activities. A webcast of t... 
Printer Friendly Version
10/25/05Seattle Genetics Reports Third Quarter 2005 Financial Results
Management Will Host Conference Call Today at 5:00 p.m. Eastern TimeBOTHELL, Wash., Oct 25, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for its third quarter and nine months ended September 30, 2005. Revenues for the third quarter of 2005 were $2.6 million, compared to $1.5 million for the third quarter of 2004. For the first nine months of 2005, revenues were $7.4 million, compared to $5.0 million for the same period in 2004. Revenues a... 
Printer Friendly Version
10/18/05Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2005 Financial Results
BOTHELL, Wash., Oct 18, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter financial results on October 25, 2005, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the financial results and provide a general corporate update. Access to the event can be obtained as follows. LIVE access on Tuesday, October 25, 2005, 2:00 p.m. Pacific time ... 
Printer Friendly Version
10/13/05Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 13, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will present at two upcoming investor conferences. The presentations will provide an overview of key company programs as well as recent and planned activities. Biotechnology Industry Organization (BIO) Investor Forum Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak on Wednesday, October 19, 2005, at 2:00 p.m. Pacific Time at the Palace Hotel in... 
Printer Friendly Version
10/04/05Seattle Genetics Expands Patent Portfolio for SGN-40 Program
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 4, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the U.S. Patent and Trademark Office (USPTO) has issued another patent relating to the company's SGN-40 program. Patent number 6,946,129, entitled "Recombinant anti-CD40 antibody and uses thereof," covers the humanized monoclonal antibody employed in the company's SGN-40 product candidate. Seattle Genetics is currently conducting phase I clinical trials of SGN-40 in multiple myelom... 
Printer Friendly Version
09/19/05Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash., Sep 19, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will participate in two upcoming investor events. The presentations will provide an overview of key company programs as well as recent and planned activities. Delafield Hambrecht -- WBBA Northwest Medical Device and Biotechnology Investor Forum Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak on Tuesday, September 20, 2005, at 11:00 a.m. Eastern time. ... 
Printer Friendly Version
08/23/05Seattle Genetics Appoints Todd Simpson as New Chief Financial Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 23, 2005-- Tim Carroll, CFO since 2000, to retire Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the appointment of Todd Simpson as Chief Financial Officer effective October 4, 2005. Mr. Simpson replaces Tim Carroll, who is retiring from the company following a transition period. "Todd brings strong biotechnology industry experience, including senior financial positions with publicly traded companies," sai... 
Printer Friendly Version
08/18/05Celera Genomics and Seattle Genetics Announce Target Selection from Research Collaboration in Cancer
ROCKVILLE, Md. & BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 18, 2005--Celera Genomics Group (NYSE:CRA), an Applera Corporation business, and Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that a Celera tumor surface antigen target has been selected for further investigation by Seattle Genetics for therapeutic development. This is the first target to be selected for advancement in the collaboration established last year between Celera Genomics and Seattle Genetics to jointly discover and ... 
Printer Friendly Version
08/04/05Seattle Genetics Adds Richard Flavell, Ph.D., to Scientific Advisory Board
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 4, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Richard A. Flavell, Ph.D., a renowned scientist with over 30 years of biotechnology and academic experience, has been added to the company's scientific advisory board. In this role, he will provide scientific input on research and development of Seattle Genetics' multiple product candidates and technologies. Dr. Flavell currently serves as Chairman and Professor of Immunobiology at Yal... 
Printer Friendly Version
07/26/05Seattle Genetics Reports Second Quarter 2005 Financial Results
BOTHELL, Wash., Jul 26, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for its second quarter ended June 30, 2005. Revenues for the second quarter of 2005 were $2.2 million, compared to $1.5 million for the second quarter of 2004. For the first six months of 2005, revenues were $4.8 million, compared to $3.5 million for the same period in 2004. Revenues are primarily driven by fees earned from the company's ongoing antibody-drug conjugate ... 
Printer Friendly Version
07/06/05Seattle Genetics Provides Update on SGN-15 Phase II Clinical Program at the World Conference on Lung Cancer
BOTHELL, Wash.--(BUSINESS WIRE)--July 6, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from its phase II clinical trials of SGN-15 at the 11th World Conference on Lung Cancer being held in Barcelona, Spain. Although the data show an encouraging trend, the company has decided to discontinue development of SGN-15, a first-generation antibody-drug conjugate (ADC), to focus on advancing its other pipeline programs and second-generation ADC technology. Seattle Genetics current... 
Printer Friendly Version
06/20/05Seattle Genetics and PSMA Development Company Announce Antibody-Drug Conjugate Collaboration
Seattle Genetics' ADC Technology to Be Utilized in Developing PSMA-targeted Therapies for Prostate Cancer BOTHELL, Wash. & TARRYTOWN, N.Y. & PRINCETON, N.J., Jun 20, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and PSMA Development Company LLC (PDC), a joint venture between Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) and Cytogen Corporation (Nasdaq:CYTO), announced today that Seattle Genetics has licensed its proprietary antibody-drug conjugate (ADC) technology to PDC. The... 
Printer Friendly Version
06/10/05Seattle Genetics Presents Data from SGN-35 Program at International Conference on Malignant Lymphoma
BOTHELL, Wash., Jun 10, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today it is presenting data from its SGN-35 development program at the 9th International Conference on Malignant Lymphoma being held June 8-11, 2005, in Lugano, Switzerland. SGN-35 is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody stably linked to a highly potent auristatin derivative using Seattle Genetics' second generation ADC technology. The company plans to ini... 
Printer Friendly Version
06/06/05Seattle Genetics to Present at Pacific Growth Equities Life Sciences Growth Conference
BOTHELL, Wash., Jun 06, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Pacific Growth Equities Life Sciences Growth Conference on Wednesday, June 8, 2005, at 1:00 p.m. Pacific time. The conference is being held at the InterContinental Mark Hopkins Hotel in San Francisco. Dr. Siegall will provide an overview of key company programs and discuss recent activities. A webcast... 
Printer Friendly Version
05/23/05Seattle Genetics to Present at the Needham Biotechnology Conference
BOTHELL, Wash.--(BUSINESS WIRE)--May 23, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric Dobmeier, Senior Vice President, Corporate Development, will speak at the Fourth Annual Needham Biotechnology Conference on Thursday, May 26, 2005, at 1:00 p.m. Eastern Time. The conference is being held at the New York Palace Hotel. Mr. Dobmeier will provide an overview of key company programs and discuss recent activities. A webcast of the presentation will be available li... 
Printer Friendly Version
05/16/05Seattle Genetics Provides Update on SGN-30 and SGN-40 Clinical Programs at ASCO
BOTHELL, Wash., May 16, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from its SGN-30 and SGN-40 clinical programs, which are being presented at the American Society of Clinical Oncology (ASCO) 2005 Annual Meeting being held in Orlando. SGN-30 is well tolerated and demonstrates objective antitumor activity in systemic anaplastic large cell lymphoma (ALCL). SGN-40 has shown evidence of biological activity in multiple myeloma, and the company has modified t... 
Printer Friendly Version
05/12/05Seattle Genetics to Present at the Banc of America Securities Health Care Conference
BOTHELL, Wash., May 12, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Banc of America Securities Health Care Conference on Tuesday, May 17, 2005, at 5:20 p.m. Pacific Time. The conference is being held at the Four Seasons Hotel in Las Vegas. Dr. Siegall will provide an overview of key company programs and discuss recent activities. A webcast of the presentation will be ... 
Printer Friendly Version
05/05/05Seattle Genetics Launches Manufacturing Campaign with Albany Molecular Research
BOTHELL, Wash., May 05, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an agreement with Albany Molecular Research, Inc. (Nasdaq:AMRI) for cGMP manufacturing of the proprietary drug-linker system employed in its SGN-35 product candidate. SGN-35 is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody stably linked to a highly potent auristatin derivative using Seattle Genetics' second generation ADC technology. ... 
Printer Friendly Version
05/03/05Seattle Genetics Receives U.S. Patent Relating to Its Antibody-Drug Conjugate Technology
BOTHELL, Wash., May 03, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has received a patent issued by the U.S. Patent and Trademark Office (USPTO) relating to the company's antibody-drug conjugate (ADC) technology. U.S. Patent No. 6,884,869 covers the drug compound monomethyl auristatin E (MMAE) and its variants, which Seattle Genetics utilizes with its proprietary linker technology to develop ADCs. By linking potent, cytotoxic drug payloads to monocl... 
Printer Friendly Version
04/28/05Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with MedImmune
BOTHELL, Wash.--(BUSINESS WIRE)--April 28, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today it has entered into an antibody-drug conjugate (ADC) collaboration with MedImmune, Inc. MedImmune will pay an upfront fee of $2.0 million for rights to utilize Seattle Genetics' ADC technology with antibodies against a single tumor target that MedImmune has selected. MedImmune also has an option to pay an additional fee to access the ADC technology for a second proprietary antibody progra... 
Printer Friendly Version
04/26/05Seattle Genetics Reports First Quarter 2005 Results
BOTHELL, Wash., Apr 26, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its first quarter ended March 31, 2005. Net loss attributable to common stockholders for the first quarter of 2005 was $7.6 million, or $0.18 per share, compared to $8.9 million, or $0.24 per share, for the same period in 2004. The net loss attributable to common stockholders in the first quarter of 2004 included a non-cash preferred stock deemed dividend of $2.2 million. ... 
Printer Friendly Version
04/21/05Seattle Genetics to Present at Invest Northwest Conference
BOTHELL, Wash., Apr 21, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at Invest Northwest on Tuesday, April 26, 2005, at 2:40 p.m. Pacific time. The conference will be held at the Bell Harbor International Conference Center in Seattle, Washington. The presentation will be webcast live and available for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. Additio... 
Printer Friendly Version
04/14/05Seattle Genetics to Present Advances in Preclinical Pipeline and ADC Technology at AACR Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--April 14, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report data from its preclinical programs and novel antibody-drug conjugate (ADC) technology during the 2005 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 16-20, 2005, in Anaheim, California. In addition, Seattle Genetics' collaborators will make multiple presentations that highlight their preclinical programs utilizing Seattle Genetic... 
Printer Friendly Version
04/13/05Seattle Genetics In-licenses Anti-CD33 Antibody Program from Protein Design Labs
BOTHELL, Wash.--(BUSINESS WIRE)--April 13, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a license agreement with Protein Design Labs, Inc. (PDL) (Nasdaq:PDLI) for exclusive rights to PDL's anti-CD33 program for both unconjugated antibody and antibody-drug conjugate (ADC) applications. "This program provides an immediate addition to our preclinical product pipeline and a near-term clinical development opportunity," stated Clay B. Siegall, Ph.D.,... 
Printer Friendly Version
03/31/05Seattle Genetics to Present at CIBC Biotechnology & Specialty Pharmaceuticals Conference
BOTHELL, Wash.--(BUSINESS WIRE)--March 31, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 5, 2005, at 1:45 p.m. Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York. Dr. Siegall will present an overview of key company programs and discuss recent activities. ... 
Printer Friendly Version
03/29/05Seattle Genetics Announces Changes to Board of Directors; Appoints Industry Veteran David Gryska
BOTHELL, Wash., Mar 29, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that David W. Gryska, an experienced biotechnology executive with substantial strategic and operational expertise, has been appointed to the company's Board of Directors. "Dave brings to the Board proven corporate partnering experience and financial acumen in the biopharmaceutical industry, including his many significant achievements at Scios," stated Clay B. Siegall, Ph.D., President ... 
Printer Friendly Version
03/15/05Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Agreement with Genentech
BOTHELL, Wash.--(BUSINESS WIRE)--March 15, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with Genentech (NYSE: DNA), triggering an undisclosed payment to Seattle Genetics. The milestone is based on Genentech's continued progress in preclinical development with an ADC utilizing Seattle Genetics' technology. "We believe our ADC technology is contributing significantly to adva... 
Printer Friendly Version
02/28/05Seattle Genetics Promotes Eric Dobmeier to Senior Vice President, Corporate Development
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 28, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier has been promoted to Senior Vice President, Corporate Development. Mr. Dobmeier will also retain the title of General Counsel, a position he has held since joining the company in March 2002. "Eric plays an integral leadership role at Seattle Genetics and has helped to shape the long-term strategy of the company through his business expertise and dedication," com... 
Printer Friendly Version
02/18/05Seattle Genetics to Present at Two Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 18, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will present at two upcoming investor conferences. The presentations will focus on the company's three clinical product candidates, three lead preclinical programs and industry-leading antibody-drug conjugate (ADC) technology. Biotechnology Industry Organization (BIO) CEO and Investor Conference Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak... 
Printer Friendly Version
02/15/05Seattle Genetics and CuraGen Expand Antibody-Drug Conjugate Collaboration
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 15, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that CuraGen Corporation (Nasdaq:CRGN) has exercised its option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration, triggering a $1.0 million payment to Seattle Genetics. Seattle Genetics entered into the ADC collaboration with CuraGen in June 2004, at which time CuraGen paid an upfront fee of $2.0 million for access to the ADC tech... 
Printer Friendly Version
02/08/05Seattle Genetics Reports Fourth Quarter and Year 2004 Results
Company ends 2004 with $106 million in cash, three product candidates in clinical trials and multiple partnerships for its proprietary antibody technologies BOTHELL, Wash., Feb 8, 2005 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for the fourth quarter and year ended December 31, 2004. Revenues for the fourth quarter of 2004 were $1.7 million, compared with $1.3 million in the fourth quarter of 2003. For the year ended December 31, 2004, revenues increa... 
Printer Friendly Version
01/27/05Seattle Genetics to Host Conference Call and Webcast Discussion of 2004 Financial Results
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 27, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) will report its fourth quarter and year 2004 results on February 8, 2005, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the financial results and provide a general corporate update. Access to the event can be obtained as follows. LIVE Access on Tuesday, February 8, 2005, 2:00 p.m. Pacific Time / 5:00 p.m. Eas... 
Printer Friendly Version
01/19/05Seattle Genetics Receives Key U.S. Patents for SGN-40 Program
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 19, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the U.S. Patent and Trademark Office (USPTO) has issued two patents relating to the company's SGN-40 program. Patents 6,838,261 and 6,843,989 claim composition of matter and methods of using anti-CD40 antibodies for the treatment of cancer. Seattle Genetics is currently conducting phase I clinical trials of SGN-40, an anti-CD40 antibody, in multiple myeloma and non-Hodgkin's lymphoma.... 
Printer Friendly Version
01/06/05Seattle Genetics to Present at JPMorgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 6, 2005--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 23rd Annual JPMorgan Healthcare Conference on Wednesday, January 12, 2005, at 2:00 p.m. Pacific time. The conference is being held at the Westin St. Francis Hotel in San Francisco. Dr. Siegall will present an overview of the company focusing on its three clinical product candidates, SGN-30, SGN-15 and SGN-... 
Printer Friendly Version
12/06/04Seattle Genetics Reports on SGN-30 and SGN-40 Clinical Programs at the American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 6, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) reported data from its SGN-30 and SGN-40 clinical programs at the American Society of Hematology (ASH) 2004 Annual Meeting in San Diego. Data from ongoing phase II studies of SGN-30 in anaplastic large cell lymphoma (ALCL) and Hodgkin's disease demonstrate that it is well tolerated and has antitumor activity. Dose escalation is continuing in a phase I trial of SGN-40 in multiple myeloma, with preliminary d... 
Printer Friendly Version
12/02/04Seattle Genetics Expands SGN-40 Clinical Program into Non-Hodgkin's Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 2, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial of SGN-40 in patients with non-Hodgkin's lymphoma. This is the company's second clinical indication for SGN-40, a humanized monoclonal antibody that targets CD40. Seattle Genetics is also conducting a phase I study of SGN-40 in multiple myeloma. "We believe SGN-40 may offer an important therapeutic option for patients with B-cell non-Hodg... 
Printer Friendly Version
11/29/04Seattle Genetics to Present at Lazard Life Sciences Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 29, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Lazard Life Sciences Conference on Tuesday, November 30, 2004. The presentation will take place at 2:30 p.m. Eastern Time at The Mandarin Oriental Hotel in New York. Dr. Siegall will present an overview of the company focusing on its three clinical product candidates, SGN-30, SGN-15 and SGN-40, its precli... 
Printer Friendly Version
11/23/04Seattle Genetics Files Shelf Registration Statement
BOTHELL, Wash., Nov 23, 2004 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). Upon being declared effective by the SEC, the registration statement will allow Seattle Genetics to sell from time to time up to $75 million of common stock. Seattle Genetics does not have any present plans for an offering pursuant to this filing. The shelf registration state... 
Printer Friendly Version
11/09/04Seattle Genetics and Genentech Expand Antibody-Drug Conjugate Collaboration
BOTHELL, Wash., Nov 9, 2004 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Genentech, Inc. (NYSE:DNA) has agreed to pay a technology access fee of $1.6 million to designate additional antigen targets under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against certain targets selected by Genentech. "We are pleased b... 
Printer Friendly Version
11/08/04Seattle Genetics to Participate in Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 8, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will speak at two upcoming investor conferences. The presentations will focus on the company's three clinical product candidates, two lead preclinical programs and industry-leading antibody-drug conjugate (ADC) technology. Both presentations will be webcast and available live and for replay via the company's website at www.seattlegenetics.com, under the news and investor information... 
Printer Friendly Version
10/26/04Seattle Genetics Reports Third Quarter 2004 Financial Results
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 26, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for its third quarter and nine months ended September 30, 2004. Revenues for the third quarter of 2004 were $1.5 million, approximately the same as revenues in the third quarter of 2003. For the first nine months of 2004, revenues were $5.0 million, compared to $3.7 million for the same period in 2003. Revenues primarily represent fees earned from the company's ongoi... 
Printer Friendly Version
10/19/04Seattle Genetics Announces Senior Research & Development Appointments
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 19, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced three appointments to the company's senior management team. Iqbal S. Grewal, Ph.D. has joined the company as Vice President, Preclinical Therapeutics; Morris Z. Rosenberg, D.Sc. has been promoted to Senior Vice President, Development; and Paul J. Carter, Ph.D. has been promoted to Vice President, Antibody Technologies. Iqbal S. Grewal, Ph.D. Vice President, Preclinical Therape... 
Printer Friendly Version
10/06/04Seattle Genetics to Present at BIO Emerging Company Investor Forum
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 6, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Biotechnology Industry Organization (BIO) Emerging Company Investor Forum on Wednesday, October 13, 2004. The presentation will take place at 11:50 a.m. Pacific Time at the Palace Hotel in San Francisco. Dr. Siegall will present an overview of the company focusing on its three clinical product candidates, ... 
Printer Friendly Version
09/28/04Seattle Genetics Announces Antibody-Drug Conjugate Agreement with Bayer Pharmaceuticals
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 28, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Bayer Pharmaceuticals Corporation (NYSE:BAY) has licensed Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. The license provides Bayer with rights to utilize Seattle Genetics' ADC technology to link cell-killing drugs to antibodies against a specific tumor target selected by Bayer. Bayer has paid Seattle Genetics a $2.0 million fee and, under the terms of... 
Printer Friendly Version
09/23/04Seattle Genetics Initiates SGN-30 Phase II Clinical Trial for Cutaneous Lymphoma
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 23, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase II clinical trial of SGN-30 for the treatment of primary cutaneous anaplastic large cell lymphoma (ALCL). Primary cutaneous ALCL, which is a type of non-Hodgkin's lymphoma that involves the skin, is the company's third clinical indication for SGN-30. The phase II study is designed to evaluate the antitumor activity and tolerability of SGN-30 in up to 40 patie... 
Printer Friendly Version
09/15/04Seattle Genetics to Participate in Two Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 15, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will present at two upcoming investor conferences. The presentations will focus on the company's three clinical product candidates, two lead preclinical programs and industry-leading antibody-drug conjugate (ADC) technology. Merriman Curhan Ford & Co. Investor Summer 2004 Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak on Monday, September 20... 
Printer Friendly Version
09/07/04Seattle Genetics Announces Douglas Williams to Step Down as Chief Scientist; Will Remain on Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 7, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the resignation of Douglas E. Williams, Ph.D., as Chief Scientific Officer and Executive Vice President, Research and Development effective as of September 10, 2004. He will remain a member of the company's Board of Directors. Dr. Williams is stepping down from his management role at Seattle Genetics to accept a position with another company. "Doug made key contributions to our resea... 
Printer Friendly Version
09/02/04Seattle Genetics to Present at NewsMakers in the Biotech Industry Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 2, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the NewsMakers in the Biotech Industry Conference on Thursday, September 9, 2004. The presentation will take place at 2:00 p.m. Eastern Time at the Millennium Broadway hotel in New York. Dr. Siegall will present an overview of the company focusing on its three clinical product candidates, SGN-30, SGN-15 and S... 
Printer Friendly Version
08/24/04Seattle Genetics Receives Orphan Drug Designation for SGN-40 in Multiple Myeloma
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 24, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its product candidate SGN-40 for multiple myeloma. SGN-40 is a humanized monoclonal antibody that Seattle Genetics is currently evaluating in a phase I clinical trial for the treatment of multiple myeloma. The company plans to initiate another phase I study of SGN-40 for the treatment of non-Hodgkin's l... 
Printer Friendly Version
07/27/04Seattle Genetics Reports Second Quarter 2004 Financial Results
BOTHELL, Wash.--(BUSINESS WIRE)--July 27, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for its second quarter ended June 30, 2004. "We continue to deliver on our clinical, preclinical and operational objectives, notably by advancing our ongoing SGN-30 phase II and SGN-40 phase I clinical trials and by initiating our next phase II clinical trial of SGN-15," commented Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We ... 
Printer Friendly Version
07/23/04Seattle Genetics Initiates SGN-15 Phase II Biomarker Clinical Trial
BOTHELL, Wash.--(BUSINESS WIRE)--July 23, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase II clinical trial of SGN-15, an antibody-drug conjugate (ADC), for the treatment of non-small cell lung cancer (NSCLC). The phase II study will utilize a biomarker to assist in evaluating the optimized dosing schedule of SGN-15 in combination with Taxotere(R), a standard chemotherapy treatment for patients with lung cancer. Completed clinical trials have demon... 
Printer Friendly Version
07/21/04Celera Genomics & Seattle Genetics Announce Collaboration to Co-Develop Targeted Antibody Therapies for Cancer
ROCKVILLE, Md. & BOTHELL, Wash.--(BUSINESS WIRE)--July 21, 2004--Celera Genomics Group (NYSE:CRA), an Applera Corporation business, and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that they have formed a strategic collaboration to jointly discover and develop antibody-based therapies for cancer. Products developed under the collaboration may include either monoclonal antibodies or antibodies linked to potent cell-killing payloads utilizing Seattle Genetics' antibody-drug-conjugat... 
Printer Friendly Version
07/13/04Seattle Genetics Establishes Preferred Antibody-Drug Conjugate Manufacturing Relationship with Albany Molecular Research, Inc.
BOTHELL, Wash.--(BUSINESS WIRE)--July 13, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a preferred provider agreement with Albany Molecular Research, Inc. (Nasdaq: AMRI) for manufacturing of its proprietary drug-linker system. The system, comprised of cell-killing drugs and stable linkers, is utilized in Seattle Genetics' antibody-drug conjugate (ADC) technology. The arrangement secures rights for Seattle Genetics' ADC licensees to work directly with... 
Printer Friendly Version
07/01/04Seattle Genetics Appoints Biotechnology Expert Franklin Berger to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--July 1, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Franklin M. Berger, CFA, a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis, has been appointed to the company's Board of Directors. "Franklin's financial expertise and extensive knowledge of the biotechnology industry will provide a valuable perspective to the company," stated Clay B. Siegall, Ph.D., President, Chief Execu... 
Printer Friendly Version
06/22/04Seattle Genetics and CuraGen Announce Antibody-Drug Conjugate (ADC) Agreement
Seattle Genetics' ADC Technology to be Used with CuraGen's Proprietary Antibodies BOTHELL, Wash. & NEW HAVEN, Conn.--(BUSINESS WIRE)--June 22, 2004-- Seattle Genetics, Inc. (Nasdaq:SGEN) and CuraGen Corporation (Nasdaq:CRGN) announced today that CuraGen has licensed Seattle Genetics' proprietary ADC technology for use with CuraGen's proprietary antibodies for the treatment of cancer. CuraGen will pay an upfront fee of $2.0 million for access ... 
Printer Friendly Version
06/05/04Seattle Genetics Reports on SGN-15 Clinical Program at ASCO
BOTHELL, Wash.--(BUSINESS WIRE)--June 5, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data on its SGN-15 program at the American Society of Clinical Oncology (ASCO) 2004 Annual Meeting being held in New Orleans. SGN-15 was evaluated in a phase II clinical trial in combination with the chemotherapy Taxotere(R) for the treatment of patients with non-small cell lung cancer (NSCLC). The data indicate that the combination of SGN-15 and Taxotere is well tolerated and resulted in im... 
Printer Friendly Version
06/03/04Seattle Genetics to Present at Three Conferences in June
BOTHELL, Wash.--(BUSINESS WIRE)--June 3, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will present at the following conferences in June. The presentations will include data describing the progress of the company's clinical and preclinical programs and its industry-leading antibody-drug conjugate (ADC) technology. Biotechnology Industry Organization (BIO) 2004 Annual International Convention Clay B. Siegall, Ph.D., President and Chief Executive Officer, ... 
Printer Friendly Version
05/19/04Seattle Genetics Expands Research Programs Through Exclusive License from Imperial College London
BOTHELL, Wash.--(BUSINESS WIRE)--May 19, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a license agreement with Imperial College Innovations Limited, the technology transfer company of Imperial College London, for exclusive rights to a novel monoclonal antibody targeting a cell surface tumor-associated antigen. Seattle Genetics plans to evaluate the therapeutic potential of the antibody against a variety of cancers, including hematologic malignancies ... 
Printer Friendly Version
05/18/04Seattle Genetics to Present at Two Upcoming Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--May 18, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the Banc of America Securities 2004 Health Care Conference on May 21, 2004, and the UBS 2004 Global Specialty Pharmaceuticals Conference on May 25, 2004. Both presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor info... 
Printer Friendly Version
05/17/04Seattle Genetics Added to NASDAQ Biotechnology Index
BOTHELL, Wash.--(BUSINESS WIRE)--May 17, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) effective with the U.S. market open on Monday, May 24, 2004. The NASDAQ Biotechnology Index was launched in 1993 and includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. T... 
Printer Friendly Version
04/27/04Seattle Genetics Reports First Quarter 2004 Results
BOTHELL, Wash.--(BUSINESS WIRE)--April 27, 2004-- Company Ends First Quarter with Three Product Candidates in Clinical Trials and $131.7 Million in Cash and Investments Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its first quarter ended March 31, 2004. Revenues for the first quarter of 2004 were $2.0 million, compared to $710,000 in the first quarter of 2003. The increase is attributable to fees earned from the company's ongoing colla... 
Printer Friendly Version
04/22/04Seattle Genetics to Present at CIBC World Markets Conference
BOTHELL, Wash.--(BUSINESS WIRE)--April 22, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 27, 2004, at 9:30 a.m. Eastern time at the Millennium Broadway hotel in New York. Dr. Siegall will provide an overview of the company focusing on its three clinical product candidates, SGN-30, SGN-15 and SG... 
Printer Friendly Version
04/01/04Seattle Genetics Names Clay B. Siegall, Ph.D., Interim Chairman of the Board
BOTHELL, Wash.--(BUSINESS WIRE)--April 1, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., has been appointed as the company's Interim Chairman of the Board of Directors, effective immediately. Dr. Siegall currently serves as Seattle Genetics' President and Chief Executive Officer, and has been a member of the Board since he co-founded the company in 1997. He replaces H. Perry Fell, Ph.D., co-founder of Seattle Genetics, who will not seek re-election... 
Printer Friendly Version
03/25/04Seattle Genetics Initiates SGN-40 Phase I Clinical Trial in Multiple Myeloma
BOTHELL, Wash.--(BUSINESS WIRE)--March 25, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase I clinical trial of SGN-40, a humanized monoclonal antibody that targets the CD40 antigen, for patients with multiple myeloma. The study is designed to evaluate the safety, pharmacokinetic profile and antitumor activity of a multi-dose regimen of SGN-40. "Commencing our SGN-40 clinical trial is an important milestone for Seattle Genetics, and expands th... 
Printer Friendly Version
03/24/04Seattle Genetics to Present Advances in Preclinical Research at AACR Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--March 24, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report data from several of its preclinical programs, including its novel antibody-drug conjugate (ADC) technology, in five poster sessions during the 2004 Annual Meeting of the American Association for Cancer Research (AACR) March 27-31 in Orlando, Florida. "Our AACR presentations demonstrate the continuing advances we are making in our research and development activit... 
Printer Friendly Version
02/26/04Seattle Genetics Receives Orphan Drug Designation for SGN-30 in T-Cell Lymphomas
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 26, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its product candidate SGN-30 for T-cell lymphomas, a category of non-Hodgkin's lymphoma that includes anaplastic and cutaneous lymphoma. SGN-30 is a monoclonal antibody currently in phase II clinical trials for the treatment of anaplastic large cell lymphoma and Hodgkin's disease. The FDA previously gra... 
Printer Friendly Version
02/24/04Seattle Genetics Announces Manufacturing Agreement with Abbott Laboratories
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 24, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an agreement with Abbott Laboratories (NYSE:ABT) for manufacturing of Seattle Genetics' SGN-30 monoclonal antibody product candidate. This antibody is also used in Seattle Genetics' SGN-35 antibody-drug conjugate (ADC) product candidate. Under the terms of the agreement, Abbott has agreed to perform scale-up and GMP manufacturing for clinical trials, as well as sup... 
Printer Friendly Version
02/19/04Seattle Genetics to Host Conference Call on February 26, 2004
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 19, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that company management will host a conference call on Thursday, February 26, 2004, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time to provide a business and financial update. Live Access on Thursday, February 26, 2004, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time 800-366-3908 (US Participants) or 303-262-2130 (International) Audio webcast a... 
Printer Friendly Version
02/18/04Seattle Genetics to Present at BIO CEO & Investor Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 18, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the BIO CEO & Investor Conference in New York on Tuesday, February 24, 2004, at 2:00 p.m. Eastern Time. A live audio webcast of Dr. Siegall's presentation can be accessed on the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. An archived version will... 
Printer Friendly Version
02/10/04Seattle Genetics Announces Completion of $66 Million Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the completion of its public offering of 7,000,000 shares of common stock. In addition, the underwriters of the public offering have exercised their over-allotment option in full and purchased an additional 1,050,000 shares of common stock. Total gross proceeds from this offering are approximately $66.4 million. CIBC World Markets Corp. and Banc of America Securities LLC acted as jo... 
Printer Friendly Version
02/05/04Seattle Genetics Announces Pricing of Common Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 5, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the pricing of its public offering of 7,000,000 shares of common stock at a price of $8.25 per share, for gross proceeds of $57.75 million. All of the shares are being sold by Seattle Genetics. The underwriters have a 30-day option to purchase an additional 1,050,000 shares to cover over-allotments, if any. CIBC World Markets Corp. and Banc of America Securities LLC are acting ... 
Printer Friendly Version
02/03/04Seattle Genetics Reports Fourth Quarter and Year 2003 Results
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 3, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for the fourth quarter and year ended Dec. 31, 2003. Revenues for the fourth quarter of 2003 were $1.3 million, compared with $635,000 in the fourth quarter of 2002. For the year ended Dec. 31, 2003, revenues were $5.1 million, compared to $1.7 million for the year ended Dec. 31, 2002. The increase in revenue is primarily attributable to fees earned from ongoing research... 
Printer Friendly Version
01/26/04Seattle Genetics Announces Proposed Common Stock Offering
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 26, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced plans to offer 7,000,000 shares of common stock in an underwritten public offering pursuant to an effective shelf registration statement. Seattle Genetics intends to grant the underwriters an option to purchase an additional 1,050,000 shares to cover over-allotments, if any. CIBC World Markets Corp. and Banc of America Securities LLC will act as joint book-running managers for the of... 
Printer Friendly Version
01/22/04Seattle Genetics Advances SGN-30 to Phase II Clinical Study
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 22, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has initiated a phase II clinical trial of SGN-30, a monoclonal antibody for the treatment of hematologic malignancies. The study is designed to evaluate the antitumor activity and safety of SGN-30 in patients with Hodgkin's disease or anaplastic large cell lymphoma. "SGN-30 represents a targeted approach to cancer therapy and may offer a much needed option for patients with ... 
Printer Friendly Version
01/12/04Seattle Genetics Announces Expansion of ADC Collaboration with Protein Design Labs
Seattle Genetics Also Obtains Rights Under PDL's Antibody Humanization Patents BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 12, 2004-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has expanded its existing antibody-drug conjugate (ADC) collaboration with Protein Design Labs (PDL) (Nasdaq:PDLI). Under the amended agreement, Seattle Genetics will provide additional research and development support to PDL for products combining PDL'... 
Printer Friendly Version
01/07/04Seattle Genetics to Present at JPMorgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 7, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the JPMorgan 22nd Annual Healthcare Conference in San Francisco on Tuesday, January 13, 2004, at 10:30 a.m. Pacific Time. A live audio webcast of Dr. Siegall's presentation can be accessed on the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. ... 
Printer Friendly Version
12/23/03Seattle Genetics Announces That Protein Design Labs Has Taken An Exclusive Antigen License Under ADC Collaboration
BOTHELL, Wash., Dec 23, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Protein Design Labs, Inc. (PDL) (Nasdaq:PDLI) has exercised an option for an exclusive license to an antigen target under the parties' antibody-drug conjugate (ADC) collaboration, triggering a payment to Seattle Genetics. "The exercise of this option by Protein Design Labs reflects the progress being made in our collaboration, and is recognition of the potential of ADCs as therape... 
Printer Friendly Version
12/19/03Seattle Genetics Receives Additional $10 Million From Genentech Under Antibody-Drug Conjugate Collaboration
BOTHELL, Wash., Dec 19, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Genentech, Inc. (NYSE:DNA) has designated additional antigen targets under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against multiple targets selected by Genentech. To secure exclusive access to the additional targets, Genentech has paid a f... 
Printer Friendly Version
12/17/03Seattle Genetics Announces Filing of Shelf Registration Statement
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 17, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). Upon being declared effective by the SEC, the registration statement will allow Seattle Genetics to sell from time to time up to $75 million of common stock. The company does not have any present plans for an offering pursuant to this registration statement. The shelf regi... 
Printer Friendly Version
12/08/03Seattle Genetics Reports Data on its SGN-30 and SGN-40 Programs at the American Society of Hematology Annual Meeting
Company plans to advance programs to their next stage of development by early 2004 BOTHELL, Wash., Dec 8, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that data from its SGN-30 phase I clinical trial and its SGN-40 preclinical program were presented at the American Society of Hematology (ASH) 2003 Annual Meeting in San Diego on Sunday, December 7, 2003. In the phase I multi-dose clinical trial, SGN-30 was well tolerated and demonstrated antitumor activit... 
Printer Friendly Version
12/05/03Seattle Genetics Announces H. Perry Fell, Ph.D., To Become Consultant to the Company
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 5, 2003-- Co-Founder to Remain Chairman of the Board Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that H. Perry Fell, Ph.D. will step down as Chief Strategy Officer at the end of 2003 and will become a consultant to the company. Dr. Fell will remain Chairman of the Board of Directors of Seattle Genetics. "Perry has played a vital role in building Seattle Genetics through his many significant contributions as... 
Printer Friendly Version
11/11/03Seattle Genetics Adds Two Oncology Veterans to Scientific Advisory Board
BOTHELL, Wash., Nov 11, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it has named Antonio Grillo-Lopez, M.D. and Michael A. Caligiuri, M.D. to its Scientific Advisory Board. Dr. Grillo-Lopez is the former Chief Medical Officer and Senior Vice President, Medical and Regulatory Affairs, of IDEC Pharmaceuticals. Dr. Caligiuri is the director of Ohio State University's Comprehensive Cancer Center. Both will provide guidance to Seattle Genetics as the compa... 
Printer Friendly Version
11/05/03Seattle Genetics to Present at CIBC World Markets Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 5, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the CIBC World Markets 14th Annual Healthcare Conference in New York City on Tuesday, November 11, 2003, at 3:30 p.m. Eastern Time. Dr. Siegall will present an overview of Seattle Genetics and discuss recent activities, including updated preliminary data from the company's SGN-15 lung study, as well as its SGN... 
Printer Friendly Version
11/04/03Seattle Genetics Names Dr. Michael McDonald Chief Medical Officer
BOTHELL, Wash., Nov 4, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Michael McDonald, M.B., Ch.B., M.R.C.P., has joined the company as Chief Medical Officer. Dr. McDonald brings to Seattle Genetics over 20 years of experience in drug development and regulatory processes, most recently at Eli Lilly where he served as Vice President, Global Clinical Research and Medical Affairs. As Chief Medical Officer, McDonald will oversee regulatory compliance, i... 
Printer Friendly Version
10/28/03Seattle Genetics Reports Third Quarter 2003 Results
Company Provides Update on SGN-15 Clinical Development Program BOTHELL, Wash., Oct 28, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for the third quarter and nine months ended September 30, 2003. Revenues for the third quarter of 2003 were $1.5 million, compared with $404,000 in the third quarter of 2002. For the first nine months of 2003, revenues were $3.7 million, compared to $1.0 million for the same period in 2002. Total operating expens... 
Printer Friendly Version
10/15/03Seattle Genetics to Present at Rodman & Renshaw Techvest Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 15, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that H. Perry Fell, Ph.D., Chairman of the Board, will speak at the Rodman & Renshaw Techvest Healthcare Conference in Boston. The presentation is scheduled for Wednesday, October 22, 2003, at 11:00 a.m. Eastern Time. A live audio webcast of the presentation can be accessed on the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section. A ... 
Printer Friendly Version
09/09/03Seattle Genetics to Present at ThinkEquity Partners Growth Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 9, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the ThinkEquity Partners Growth Conference at the Omni San Francisco Hotel. Dr. Siegall will present an overview of the company and discuss recent activities. The presentation is scheduled for Tuesday, September 16, 2003, at 10:00 a.m. Pacific Time. A webcast of the presentation will be available live ... 
Printer Friendly Version
09/03/03Seattle Genetics Promotes Eric Dobmeier to Vice President, Corporate Affairs
BOTHELL, Wash., Sep 3, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the promotion of Eric L. Dobmeier, J.D., to Vice President, Corporate Affairs. Mr. Dobmeier will also retain the title of General Counsel, a position he has held since joining the company in March 2002. "Eric has made significant legal and operational contributions to Seattle Genetics, including his role in our recent $41 million financing," stated Clay B. Siegall, Ph.D., President and ... 
Printer Friendly Version
08/12/03Seattle Genetics Reports Encouraging SGN-15 Data at World Conference on Lung Cancer
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 12, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced that data from its phase II clinical trial of SGN-15 in non-small cell lung cancer (NSCLC) will be presented today by Helen J. Ross, M.D. at the 10th World Conference on Lung Cancer in Vancouver, Canada. Dr. Ross, who is a principal investigator on the trial, is the co-director of the Thoracic Oncology Program at the Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Ore... 
Printer Friendly Version
08/11/03Seattle Genetics Reports Progress in its SGN-35 Program
BOTHELL, Wash., Aug 11, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the publication of preclinical data on its SGN-35 product candidate, an antibody-drug conjugate (ADC), in the August 15, 2003 issue of Blood, the Journal of the American Society of Hematology. The research illustrates that SGN-35 is highly efficacious at low doses and is capable of selectively targeting CD30-positive malignancies in models of Hodgkin's disease and certain types of non... 
Printer Friendly Version
07/29/03Seattle Genetics Reports Second Quarter 2003 Results
BOTHELL, Wash.--(BUSINESS WIRE)--July 29, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for the second quarter and six months ended June 30, 2003. "We have achieved numerous preclinical, clinical and operational accomplishments over the past several months," commented Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Notably, we strengthened our financial position by completing a $41 million financing and expanded our management ... 
Printer Friendly Version
07/29/03Seattle Genetics and Genencor International Extend Collaboration Agreement
BOTHELL, Wash. & PALO ALTO, Calif., Jul 29, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Genencor International, Inc. (Nasdaq:GCOR) announced today that they have agreed to extend and modify certain terms of their collaboration agreement established in January 2002. Under the amended agreement, Genencor will pay Seattle Genetics a fee to extend the term of the collaboration by two additional years and obtain a non-exclusive license to Seattle Genetics' proprietary ... 
Printer Friendly Version
07/28/03Seattle Genetics Receives Orphan Drug Designation from the FDA for SGN-30
BOTHELL, Wash., Jul 28, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its product candidate SGN-30 for patients with Hodgkin's disease. SGN-30 is a monoclonal antibody that is in an ongoing phase I/II clinical trial for the treatment of CD30-positive hematologic malignancies, including Hodgkin's disease, anaplastic large cell lymphoma and other types of lymphomas. ... 
Printer Friendly Version
07/17/03Seattle Genetics Names Douglas Williams, Ph.D., Chief Scientific Officer and Executive Vice President, R&D
BOTHELL, Wash., Jul 17, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Douglas E. Williams, Ph.D. will join the company as Chief Scientific Officer and Executive Vice President, Research and Development. He will also continue to be a member of Seattle Genetics' Board of Directors, a position he has held since May 2001. Dr. Williams brings to Seattle Genetics over 15 years of biotechnology experience. He joined Immunex Corporation as a staff scie... 
Printer Friendly Version
07/02/03Seattle Genetics' Stockholders Approve $41 Million Financing
BOTHELL, Wash.--(BUSINESS WIRE)--July 2, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its stockholders approved a $41 million private placement transaction at a special meeting of stockholders held this morning. Subject to customary closing conditions, the company expects the transaction to be completed within five business days. "This financing will increase Seattle Genetics' cash and investment balance to over $70 million, enabling us to build long-term stockho... 
Printer Friendly Version
06/17/03Seattle Genetics Achieves Milestones Under Antibody-Drug Conjugate Collaboration with Celltech Group
BOTHELL, Wash.--(BUSINESS WIRE)--June 17, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has achieved two preclinical production milestones under its antibody-drug conjugate (ADC) collaboration agreement with Celltech Group (LSE:CCH) (NYSE:CLL), which trigger certain payments to Seattle Genetics. The two companies formed the collaboration in March 2002 to provide Celltech with a license to Seattle Genetics' ADC technology for use with Celltech's antibodies and an... 
Printer Friendly Version
06/05/03Seattle Genetics Publishes Preclinical Antibody-Drug Conjugate Technology Research In Nature Biotechnology
BOTHELL, Wash.--(BUSINESS WIRE)--June 5, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the publication of preclinical data related to its proprietary antibody-drug conjugate (ADC) technology in Nature Biotechnology. The research involves the development and activities of a novel class of ADCs composed of highly potent, synthetic drugs chemically attached to monoclonal antibodies through stable linkage systems. The publication is currently available online and will be pr... 
Printer Friendly Version
06/02/03Seattle Genetics Reports Progress In Clinical Development of Antibody-Based Therapies for Cancer; Company presents data from four clinical studies at ASCO 2003 Annual Meeting
BOTHELL, Wash., Jun 2, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported clinical data from trials of its SGN-30 and SGN-15 product candidates at the American Society of Clinical Oncology (ASCO) 2003 Annual Meeting being held in Chicago. SGN-30 was shown to be safe with a favorable pharmacokinetic profile and demonstrated antitumor activity in some patients with hematologic malignancies in an initial phase I single dose study. SGN-15 was evaluated in combinat... 
Printer Friendly Version
05/13/03Seattle Genetics Announces Definitive Agreement for $40 Million Financing
Conference Call Scheduled for 1:30 p.m. Pacific Time on May 13, 2003 BOTHELL, Wash.--(BUSINESS WIRE)--May 13, 2003-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a definitive purchase agreement for the sale of $40 million of Series A convertible preferred stock and warrants to purchase common stock. The private placement, which is subject to approval by Seattle Genetics' stockholders, will be led by JPMorgan Partners, LLC and Baker Brothers... 
Printer Friendly Version
04/28/03Seattle Genetics Scheduled to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference
BOTHELL, Wash.--(BUSINESS WIRE)--April 28, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference at the Millennium Broadway Hotel in New York. Dr. Siegall's presentation will focus on Seattle Genetics' lead product candidates, SGN-30, SGN-40 and SGN-15. The presentation is scheduled for Thursday, May 1, 2003 at 8... 
Printer Friendly Version
04/22/03Seattle Genetics Reports First Quarter 2003 Results
BOTHELL, Wash., Apr 22, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its first quarter ended March 31, 2003. Revenues for the first quarter of 2003 were $710,000, compared with $269,000 in the first quarter of 2002. The increase is attributable to fees earned from ongoing research collaborations. Total operating expenses for the first quarter of 2003 were $7.0 million, compared to $6.8 million for the first quarter of 2002. Research and ... 
Printer Friendly Version
04/08/03Seattle Genetics Reports Antibody-Drug Conjugate Research Data
BOTHELL, Wash., Apr 8, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from its antibody-drug conjugate (ADC) research programs. Three abstracts describing these findings were published in the 2003 Proceedings of the Annual Meeting of the American Association for Cancer Research (AACR) and were to be presented during that organization's recently cancelled annual meeting in Toronto, Canada. "These data demonstrate some of the significant advances th... 
Printer Friendly Version
03/06/03Seattle Genetics Scheduled to Present at Invest Northwest 2003
BOTHELL, Wash., Mar 6, 2003 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at Invest Northwest on Tuesday, March 11, 2003 at 9:20 a.m. Pacific Time. The conference is being held at the Bell Harbor Conference Center in Seattle. A webcast of the presentation will be available live and for replay. The webcast can be accessed on the Seattle Genetics website, www.seattlegenetics.com, under... 
Printer Friendly Version
02/19/03Seattle Genetics Announces Key Scientific Additions
Paul J. Carter, Ph.D. Named Senior Director, Antibody Technologies William J. Murphy, Ph.D. Joins Scientific Advisory Board BOTHELL, Wash., Feb 19, 2003 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Paul J. Carter, Ph.D. has joined the company as Senior Director, Antibody Technologies and William J. Murphy, Ph.D., Professor at University of Nevada Medical School, has been added to its Scientific Advisory Board. Paul Carter, Ph.D., 42, brings 17 years of... 
Printer Friendly Version
01/30/03Seattle Genetics Reports Fourth Quarter and Year 2002 Results
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 30, 2003--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its fourth quarter and year ended December 31, 2002. Revenues for the fourth quarter of 2002 were $635,000, up from $169,000 in the fourth quarter of 2001. For the year ended December 31, 2002, revenues were $1.7 million, compared to $274,000 for the year ended December 31, 2001. The increase in revenue is primarily attributable to fees earned from resear... 
Printer Friendly Version
01/02/03Seattle Genetics Scheduled to Present at JPMorgan H&Q Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 2, 2003--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the JPMorgan H&Q 21st Annual Healthcare Conference on Monday, January 6, 2003 at 10:00 a.m. Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco. A webcast of the presentation will be available live and for replay. The webcast can be ac... 
Printer Friendly Version
12/05/02Clinical Data on Seattle Genetics Monoclonal Antibody SGN-30 To Be Presented at American Society of Hematology Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 5, 2002--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that clinical data on its product candidate SGN-30 will be presented during the 44th Annual Meeting and Exposition of the American Society of Hematology (ASH) held in Philadelphia, PA. SGN-30 is a monoclonal antibody being developed for the treatment of various hematologic malignancies, including Hodgkin's disease and certain other lymphomas. Nancy L. Bartlett, M.D., fr... 
Printer Friendly Version
11/27/02Seattle Genetics Announces Appointment of Clay B. Siegall, Ph.D. as Chief Executive Officer
H. Perry Fell, Ph.D. to Continue as Chairman of the Board and Chief Strategy Officer BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 27, 2002-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D. has been promoted to President and Chief Executive Officer. Dr. Siegall was previously President and Chief Scientific Officer. H. Perry Fell, Ph.D., who has served as the company's Chief Executive Officer since 1997, wi... 
Printer Friendly Version
11/07/02Seattle Genetics Advances SGN-30 to Multi-Dose Phase I/II Clinical Trial, Provides Update On SGN-15 and Closes Its SGN-10 Clinical Program
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 7, 2002--Seattle Genetics, Inc. (Nasdaq:SGEN) reported today on the clinical status of its SGN-30, SGN-15 and SGN-10 product candidates. SGN-30 Phase I/II Clinical Trial Initiated Seattle Genetics announced the initiation of a phase I/II, multi-dose study of its product candidate SGN-30, a monoclonal antibody that targets and kills CD30-expressing hematologic malignancies. The study, which is being conducted at 10 sit... 
Printer Friendly Version
10/31/02Seattle Genetics Scheduled to Present at CIBC World Markets Thirteenth Annual Health Care Conference
BOTHELL, Wash., Oct 31, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that H. Perry Fell, Ph.D., Chairman and Chief Executive Officer, will speak at the CIBC World Markets Thirteenth Annual Health Care Conference on Tuesday, November 5, 2002 at 10:30 a.m. Eastern Time. The conference is being held at The Plaza Hotel in New York City. A webcast of the presentation will be available live and for replay. The webcast can be accessed on the Seattle Genetics ... 
Printer Friendly Version
10/22/02Seattle Genetics Reports Third Quarter 2002 Results
BOTHELL, Wash., Oct 22, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its third quarter and nine months ended September 30, 2002. Revenues for the third quarter of 2002 were $404,000, compared with $70,000 in the third quarter of 2001. For the first nine months of 2002, revenues were $1.0 million, compared to $105,000 for the same period in 2001. Total operating expenses for the third quarter of 2002 decreased to $6.0 million, compared to $7... 
Printer Friendly Version
10/08/02Seattle Genetics Provides Update On SGN-14
BOTHELL, Wash., Oct 8, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has received notification from Genentech (NYSE:DNA) that Genentech will not continue development of the product candidate SGN-14 (PRO64553). Genentech licensed SGN-14, an anti-CD40 monoclonal antibody, from Seattle Genetics in June 1999. Under the terms of the license agreement with Genentech, Seattle Genetics will have the right to develop SGN-14 on its own with Genentech receiv... 
Printer Friendly Version
10/07/02Seattle Genetics Enters Into Manufacturing Relationship With Albany Molecular Research
BOTHELL, Wash., Oct 7, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into a relationship with Albany Molecular Research, Inc. (Nasdaq:AMRI) for the development and manufacture of its proprietary drug-linker systems. These systems, comprised of cell-killing drugs and stable linkers, are the fundamental component of Seattle Genetics' antibody-drug conjugate (ADC) technology platform. "Increasing the potency of monoclonal antibodies by... 
Printer Friendly Version
09/17/02Seattle Genetics Awarded National Institutes of Health Funded Research Grant
BOTHELL, Wash., Sep 17, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it was awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) through the National Cancer Institute (NCI). The $128,800 grant was awarded to develop anti-cancer prodrugs that can be activated by tumor-associated enzymes. This is the third SBIR grant the company has received in as many years. Prodrugs are a class of drug that are in... 
Printer Friendly Version
09/06/02Seattle Genetics Names Peter D. Senter Vice President, Chemistry
BOTHELL, Wash., Sep 6, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the promotion of Peter D. Senter, Ph.D. to Vice President, Chemistry. Dr. Senter is responsible for the ongoing research of potent small molecule drugs and stable linker systems for use in the company's antibody-drug conjugate (ADC) technology platform. Dr. Senter also leads Seattle Genetics' research efforts in the area of antibody-directed enzyme prodrug therapy (ADEPT). "Peter has ... 
Printer Friendly Version
09/04/02Seattle Genetics Reports Findings From SGN-30 Phase I Clinical Study
BOTHELL, Wash., Sep 4, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported the successful completion of its first phase I clinical trial with the therapeutic monoclonal antibody SGN-30. The study was designed as a rapid dose escalation to evaluate the safety and pharmacokinetic profile of a single dose of SGN-30 in patients with hematologic malignancies such as Hodgkin's disease, anaplastic large cell lymphoma and certain other lymphomas. Thirteen patients we... 
Printer Friendly Version
08/20/02Seattle Genetics Initiates Phase II Clinical Trial of SGN-15 in Advanced Ovarian Cancer
BOTHELL, Wash., Aug 20, 2002 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the initiation of a phase II clinical trial of its antibody-drug conjugate product candidate SGN-15 (cBR96-doxorubicin immunoconjugate) for patients with advanced ovarian cancer. The trial will evaluate SGN-15 in combination with the chemotherapeutic drug Gemzar(R) (gemcitabine). "We are pleased to begin this study of SGN-15 in combination with Gemzar, a chemotherapeutic agent used b... 
Printer Friendly Version
07/23/02Seattle Genetics Reports Second Quarter 2002 Results
BOTHELL, Wash., Jul 23, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its second quarter ended June 30, 2002. Revenues for the second quarter of 2002 were $376,000, compared with $35,000 in the second quarter of 2001. For the first six months of 2002, revenues were $645,000, compared to $35,000 for the same period in 2001. As of June 30, 2002, Seattle Genetics had $53.0 million in cash, cash equivalents and investments, an increase of $800,00... 
Printer Friendly Version
07/22/02Seattle Genetics Receives License Fee From Genencor
Collaboration Toward Development of Cancer Therapeutics Using Targeted Enzymes and Prodrugs BOTHELL, Wash., Jul 22, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it received a license fee in an undisclosed amount from Genencor International, Inc. (Nasdaq:GCOR) under the terms of a strategic alliance formed by the two companies in January 2002. The collaboration involves the joint discovery and development of a class of cancer therapeutics based on tu... 
Printer Friendly Version
07/11/02Seattle Genetics Publishes Preclinical Findings of Monoclonal Antibody SGN-30 In Cancer Research
BOTHELL, Wash., Jul 11, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the publication of preclinical data related to the monoclonal antibody SGN-30 in the July 1 issue of Cancer Research (Vol. 62:3736-3742). The data demonstrate that SGN-30 induces tumor cell death, or apoptosis, in culture and is efficacious in models of Hodgkin's disease. These preclinical findings provided the basis for the company's ongoing phase I study of SGN-30 for the treatment of... 
Printer Friendly Version
06/04/02Seattle Genetics Appoints Douglas Southern to Board of Directors
Former Immunex CFO to Chair Audit Committee BOTHELL, Wash., Jun 4, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the appointment of Douglas Southern to its Board of Directors and as Chairman of its Audit Committee. Mr. Southern served for nine years as Senior Vice President and Chief Financial Officer at Immunex Corporation (Nasdaq:IMNX) prior to retiring in 1999. This appointment expands Seattle Genetics' Board to eight members. "Doug's extensive e... 
Printer Friendly Version
05/21/02Seattle Genetics Updates Clinical Progress and Plans
Data to be Presented at ASCO Meeting BOTHELL, Wash., May 21, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report certain clinical trials data on its product candidates SGN-15 and SGN-10 during the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Fla. The company will present data on its SGN-15 phase II breast and colon studies as well as its SGN-10 phase I single agent study in poster presentations o... 
Printer Friendly Version
04/29/02Seattle Genetics Scheduled to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference
BOTHELL, Wash., Apr 29, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, May 1, 2002 at 9:30 a.m. Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York, New York. A webcast of the presentation will be available live and for replay. The webcast... 
Printer Friendly Version
04/25/02Seattle Genetics Releases First Quarter 2002 Results
BOTHELL, Wash., Apr 25, 2002 (BW HealthWire) -- Company reports expansion of clinical trials, growth in preclinical initiatives and new research collaborations Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its first quarter ended March 31, 2002. Revenues for the first quarter of 2002 were $269,000, compared with no revenue in the first quarter of 2001. The 2002 revenues are primarily attributable to fees earned from research collaborations. Total operating exp... 
Printer Friendly Version
04/22/02Seattle Genetics Announces Antibody-Drug Conjugate Agreement With Genentech
BOTHELL, Wash.--(BW HealthWire)--April 22, 2002--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Genentech, Inc. (NYSE:DNA) has licensed Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology for use with Genentech's antibodies targeted to certain diseases. The agreement provides Genentech with broad access to Seattle Genetics' ADC technology for use with therapeutic antibodies recognizing multiple target antigens. Genentech intends to utilize th... 
Printer Friendly Version
04/08/02Seattle Genetics to Present Preclinical Data at AACR Meeting
BOTHELL, Wash., Apr 8, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report preclinical data describing the progress of certain of its monoclonal antibody-based therapeutics during the 93rd Annual Meeting of the American Association of Cancer Research (AACR) in San Francisco, CA, April 6th through 10th. The Company will present advances in its antibody-drug conjugate (ADC) technology, the genetically engineered monoclonal antibody SGN-30 tha... 
Printer Friendly Version
04/01/02Seattle Genetics Names CEO as Chairman and Appoints General Counsel
BOTHELL, Wash., Apr 1, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that H. Perry Fell, Ph.D. has been appointed as the Company's Chairman of the Board. Dr. Fell co-founded Seattle Genetics and serves as Chief Executive Officer. He has been a member of the Board since the Company's inception. He replaces Charles (Chad) P. Waite, who will continue to serve as a director. Mr. Waite is General Partner at OVP Venture Partners and has served as Seattle Genet... 
Printer Friendly Version
03/28/02Celltech and Seattle Genetics Announce Antibody-Drug Conjugate Collaboration
SLOUGH, England, and BOTHELL, Wash., Mar 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celltech Group plc (LSE: CCH; NYSE: CLL) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced a multi-target collaboration to use Seattle Genetics' antibody-drug conjugate technology with Celltech's antibody fragments directed against specific diseases, including immunological targets. Seattle Genetics has developed synthetic, highly potent, novel drugs that can be used as payloads to dramatica... 
Printer Friendly Version
03/21/02Seattle Genetics Initiates Phase I Clinical Trial with Monoclonal Antibody SGN-30
BOTHELL, Wash., Mar 21, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of its first phase I clinical trial with the therapeutic monoclonal antibody SGN-30 for the treatment of hematologic malignancies. The single agent study is designed as a rapid dose escalation to assess the safety and pharmacokinetic profile of SGN-30 in patients with hematologic malignancies such as Hodgkin's disease, anaplastic large cell lymphoma and certain other lymp... 
Printer Friendly Version
03/14/02Seattle Genetics Licenses Monoclonal Antibodies from Mabtech AB
BOTHELL, Wash., Mar 14, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an agreement to license certain monoclonal antibodies from Mabtech AB, located in Sweden. The agreement includes multiple antibodies that target cell surface molecules on a variety of cancer cell types. Seattle Genetics has development, manufacturing and worldwide commercialization rights to therapeutic products derived from the antibodies. Seattle Genetics w... 
Printer Friendly Version
01/31/02Seattle Genetics Reports Fourth Quarter and Year 2001 Results
BOTHELL, Wash., Jan 31, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its fourth quarter and year ended December 31, 2001. Revenues for the fourth quarter of 2001 were $169,000, up from revenues of $16,000 in the fourth quarter of 2000. For the year ended December 31, 2001, revenues were $274,000, compared to $99,000 for the same period in 2000. The increase in revenue is primarily attributable to fees earned from certain research collaboration... 
Printer Friendly Version
01/08/02Seattle Genetics Announces That Its Anti-CD40 Monoclonal Antibody Enters Clinical Development At Genentech
BOTHELL, Wash., Jan 8, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that its anti-CD40 monoclonal antibody (mAb) has entered the Genentech, Inc. (NYSE:DNA) clinical development portfolio. The product candidate, PRO64553, is a humanized mAb targeted to CD40 and is being developed for the treatment of various hematologic malignancies. PRO64553 originated as part of a Seattle Genetics research program as the compound SGN-14 and was licensed to Genentech i... 
Printer Friendly Version
01/07/02Genencor and Seattle Genetics Announce Collaboration To Advance Targeted Cancer Therapies
Lead Product Candidate for Metastatic Melanoma Will Be Developed Jointly PALO ALTO, Calif. and BOTHELL, Wash., Jan 7, 2002 /PRNewswire via COMTEX/ -- Genencor International, Inc. (Nasdaq: GCOR) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that they have formed a strategic alliance to jointly discover and develop a class of cancer therapeutics based on tumor-targeted enzymes that activate prodrugs. The two companies will share preclinical and clinical development costs an... 
Printer Friendly Version
01/04/02Seattle Genetics Appoints New Member to its Scientific Advisory Board
BOTHELL, Wash., Jan 4, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the appointment of Bruce R. Blazar, M.D. to its Scientific Advisory Board. Dr. Blazar is a Professor in the Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplant at the University of Minnesota in Minneapolis and is the Andersen Chair in Transplantation Immunology. The appointment of Dr. Blazar brings the number of Seattle Genetics scientific advisors ... 
Printer Friendly Version
01/03/02Seattle Genetics Scheduled to Present at JPMorgan H&Q Healthcare Conference
BOTHELL, Wash., Jan 3, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that H. Perry Fell, Ph.D., Chief Executive Officer and Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the JPMorgan H&Q 20th Annual Healthcare Conference on Tuesday, January 8, 2002 at 2:00 p.m. Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco, California. A webcast of the presentation will be available live and ... 
Printer Friendly Version
11/01/01Seattle Genetics Scheduled to Present at CIBC Healthcare Conference
Bothell, WA — November 1, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets Twelfth Annual Healthcare Conference on Tuesday, November 6, 2001 at 11:00 a.m. Eastern Time. The conference is being held at The Plaza Hotel in New York City. A webcast of the presentation will be available live and for replay. The webcast can be accessed on the Seattle Genetics website, www.s... 
Printer Friendly Version
10/23/01Seattle Genetics Reports Third Quarter 2001 Results
Bothell, WA — October 23, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its third quarter and nine months ended September 30, 2001. Revenues for the quarter were $70,000, compared to revenues of $27,000 in the third quarter of 2000. For the first nine months of 2001, revenues were $105,000, compared to $83,000 for the same period in 2000. Revenues for the quarter were attributable to fees earned from research collaborations and proceeds from a National Institut... 
Printer Friendly Version
10/22/01Seattle Genetics Licenses Potent Cell-Killing Drugs from Proacta Therapeutics
Bothell, WA – October 22, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that they have entered into an agreement to license certain cell-killing drugs from Proacta Therapeutics, based in Auckland, New Zealand. Seattle Genetics intends to evaluate the highly potent, synthetic drugs as product candidates on their own as well as to utilize them in its antibody-drug conjugate program. Under the terms of the agreement, Seattle Genetics will have exclusive development, manufacturing... 
Printer Friendly Version
10/05/01Seattle Genetics Scheduled to Present at UBS Warburg Global Life Sciences Conference
Bothell, WA — October 5, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that H. Perry Fell, Ph.D., Chief Executive Officer, will speak at the UBS Warburg Global Life Sciences Conference on Tuesday, October 9, 2001 at 8:40 a.m. Eastern Time. The public is invited to listen to the presentation by calling the following numbers established by UBS Warburg: Live: 800-500-0177 (domestic) or 719-457-2679 (international) Replay: 800-759-8603 (domestic) 402-220-8537 (intern... 
Printer Friendly Version
09/26/01Seattle Genetics Scheduled at Raymond James Healthcare Conference
Bothell, WA — September 26, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that H. Perry Fell, Ph.D., Chief Executive Officer, will speak at the Raymond James & Associates Healthcare Conference on Monday, October 1, 2001 at 2:50 p.m. Central Time. The conference is being held at the Nashville Convention Center in Nashville, Tennessee. A webcast of the presentation will be available live and for replay. The webcast can be accessed on the Seattle Genetics website, www.seat... 
Printer Friendly Version
09/19/01Seattle Genetics Awarded National Institutes of Health Funded Research Grant
Bothell, WA – September 19, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it was awarded a research grant by the National Institutes of Health (NIH) to support the Company’s development of monoclonal antibody-drug conjugates for the treatment of cancer. The grant was awarded under the Small Business Innovation Research (SBIR) Program of the NIH. “This grant helps to support the continued development of our antibody-drug conjugate technology and is a validation by th... 
Printer Friendly Version
08/21/01Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer
Bothell, WA – August 21, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced the initiation of a phase II clinical trial for patients with non-small cell lung cancer with its product candidate, SGN-15, a monoclonal-antibody drug conjugate. The trial will evaluate SGN-15 in combination with the chemotherapeutic drug Taxotere®. “This is the fourth potential indication for SGN-15, complementing our existing trials in breast, colon and prostate cancers,” stated H. Perry Fell, Ph.D., Chi... 
Printer Friendly Version
08/16/01Seattle Genetics Announces Business Update Meeting and Webcast
Bothell, WA — August 16, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) company management will host a business update meeting on August 21, 2001 at approximately 3:45 p.m. Pacific Time. The session will include presentations on research, development and clinical trial activities. Scheduled presenters include H. Perry Fell, Ph.D., Chief Executive Officer, Clay B. Siegall, Ph.D., President and Chief Scientific Officer and Tim Carroll, Chief Financial Officer. A webcast of the presentatio... 
Printer Friendly Version
08/14/01Seattle Genetics Signs Development and Manufacturing Agreement with ICOS for the Monoclonal Antibody Component of SGN-15
Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has entered into an agreement with ICOS Corporation (Nasdaq: ICOS) for the development and manufacture of the monoclonal antibody component of its lead antibody-drug conjugate SGN-15. Under the terms of the agreement, ICOS will perform process development, scale-up and GMP manufacturing. SGN-15 is presently being tested in phase II trials for the treatment of breast, colon and prostate canc... 
Printer Friendly Version
08/14/01Seattle Genetics Announces Relocation and Expansion of Corporate Headquarters
Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has relocated its corporate office and laboratory space to a new, significantly larger facility, located a short distance from their former site in Bothell’s Canyon Park area. The new headquarters building, which is 64,000 square feet, will allow for growth in all areas of the Company, including clinical, research and development. Seattle Genetics’ new address is 21823 30th Drive S.E., Both... 
Printer Friendly Version
07/24/01Seattle Genetics Reports Second Quarter 2001 Results
Bothell, WA — July 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its second quarter ended June 30, 2001. Revenues for the quarter were $35,000, compared to revenues of $36,000 in the second quarter of 2000. For the first six months of 2001, revenues were $35,000, compared to $56,000 for the same period in 2000. Revenues for the quarter are attributable to the Company’s collaboration with Eos Biotechnology, where the majority of the upfront payment from the collab... 
Printer Friendly Version
07/18/01Seattle Genetics Licenses Monoclonal Antibodies from CLB-Research and Development
Bothell, WA – July 18, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has entered into an agreement to license certain monoclonal antibodies that target cancer and immunological disease from CLB-Research and Development, located in the Netherlands. Seattle Genetics will have development, manufacturing and worldwide commercialization rights to therapeutic products derived from the antibodies. Seattle Genetics will evaluate the antibodies as therapeutic ag... 
Printer Friendly Version
07/11/01Seattle Genetics Announces Date of Second Quarter Results and Conference Call
BOTHELL – July 11, 2001 --- Seattle Genetics (Nasdaq: SGEN) will release second quarter 2001 results on Tuesday, July 24, 2001, after the close of U.S. financial markets. This announcement will be available on the Seattle Genetics website at www.seattlegenetics.com. Additionally, Seattle Genetics executives will host a conference call to discuss the results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern) on July 24th. A webcast of the live call can be accessed from the “News and Investor... 
Printer Friendly Version
07/10/01Seattle Genetics Names Morris Rosenberg Vice President, Development
Company expands its product development and clinical manufacturing initiatives Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of Morris Z. Rosenberg as Vice President, Development. Dr. Rosenberg will be responsible for overseeing all aspects of development through to clinical trials, including process development, quality assurance and manufacturing. “As the Company continues to bring forward its pipeline of monoclonal anti... 
Printer Friendly Version
07/10/01Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes
Bothell, WA – July 10, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has been added to the Russell 2000® and Russell 3000® stock indexes. These Russell Indexes, issued by the Frank Russell Company, are adjusted annually based on market capitalization as of May 31st. The annual rebalancing process ensures that the index provides an accurate reflection of current stock market activity and performance. The Russell 3000, a broad market stock index, measur... 
Printer Friendly Version
06/05/01Seattle Genetics and Eos Biotechnology Collaborate To Develop Next Generation Antibody-Drug Conjugates For Cancer Therapy
Bothell, WA and South San Francisco, CA – June 5, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Eos Biotechnology, Inc. announced today a collaboration to use Seattle Genetics’ toxic payload technology with Eos’ proprietary monoclonal antibodies directed against novel cancer targets derived from their analyses of the human genome. Seattle Genetics has fully synthetic, highly potent, novel drugs that can be used as payloads to dramatically increase the potency of monoclonal antibodies as the... 
Printer Friendly Version
05/17/01Seattle Genetics Appoints New Members to its Board of Directors and Scientific Advisory Board
Immunex’s Executive Vice President Douglas E. Williams, Ph.D. Added to Board of Directors Noted Cancer Expert Dan L. Longo, M.D. Added to Scientific Advisory Board Bothell, WA – May 17, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the appointment of new members to both its Board of Directors and its Scientific Advisory Board. Douglas E. Williams, Ph.D., Executive Vice President, Chief Technology Officer and Director of Immunex Corporation (Nasdaq: IMNX) was app... 
Printer Friendly Version
05/01/01Seattle Genetics Scheduled at CIBC World Markets Bio-Technology Conference
Bothell, WA — May 1, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets First Annual Bio-Technology Conference on May 2, 2001 at 10:25 a.m. Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York. A webcast of the presentation will be available in real-time and for replay. The webcast can be accessed on the Seattle Genetics website, www.se... 
Printer Friendly Version
04/24/01Seattle Genetics Reports First Quarter Results
Bothell, WA — April 24, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its first quarter ended March 31, 2001. Net loss for the quarter was $4.2 million, or $0.46 per share, compared to a net loss of $0.9 million, or $.30 per share for the same period in 2000. On a pro forma basis, which excludes non-cash stock-based compensation, depreciation and amortization, the Company reported a loss of $2.9 million, or $0.32 per share, for the first quarter of 2001 as compared t... 
Printer Friendly Version
03/07/01Seattle Genetics Announces Initial Public Offering
Bothell, WA – March 7, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today the pricing of its initial public offering of 7,000,000 shares of common stock at $7.00 per share. The offering includes a $2 million investment, or 285,714 shares, purchased directly by Genentech, Inc. JP Morgan and CIBC World Markets are co-lead managers of the offering, with JP Morgan acting as sole bookrunning manager. Banc of America Securities LLC is acting as a co-manager. The underwriters were also ... 
Printer Friendly Version
02/07/01Seattle Genetics and Medarex Establish Alliance to Develop Human Antibody Therapeutics
Medarex to invest $2 million in Seattle Genetics Bothell, WA and Princeton, NJ: February 7, 2001— Seattle Genetics, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced the formation of a strategic alliance through which the two companies expect to utilize Medarex's UltiMAb™ Human Antibody Development SystemSM to jointly develop and commercialize monoclonal antibody-based therapeutic products against specific cancer targets. Under this alliance, Seattle Genetics will provide t... 
Printer Friendly Version
11/30/00Seattle Genetics Initiates Phase II Clinical Trial in Prostate Cancer
Bothell, WA – November 30, 2000 – Seattle Genetics, Inc. announced the initiation of a phase II clinical trial with one of its lead drug candidates, SGN-15. The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere® for patients with hormone refractory prostate cancer. The study is planned for as many as 15 sites in the U.S. with the lead site at Arizona Cancer Center in Tucson, AZ. About Prostate Cancer Prostate... 
Printer Friendly Version
11/20/00Seattle Genetics Files For Initial Public Offering of Common Stock
Bothell, WA - November 20, 2000 - Seattle Genetics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for an initial public offering of its common stock. All of the shares to be registered will be offered by Seattle Genetics. J.P. Morgan & Co. and CIBC World Markets are co-lead managers of the offering, with J.P. Morgan acting as sole bookrunning manager. Banc of America Securities LLC is acting as a co-manager. Copies of the ... 
Printer Friendly Version
11/09/00Seattle Genetics Signs Development and Manufacturing Agreement with ICOS
Bothell, WA - November 9, 2000 – Seattle Genetics, Inc. announced today that it has signed a development and manufacturing agreement with ICOS Corporation (Nasdaq:ICOS). Under the terms of the agreement, ICOS will conduct development, scale-up and manufacturing in its cell culture manufacturing facility to provide qualified, GMP grade product for clinical testing. The drug candidate being developed is a monoclonal antibody for cancer therapy. Seattle Genetics retains the rights to com... 
Printer Friendly Version
10/31/00Seattle Genetics Initiates Phase II Clinical Trials With SGN-15
Two Trials Commencing for Patients With Breast or Colorectal Cancers Bothell, WA – October 31, 2000 – Seattle Genetics, Inc. announced the initiation of phase II clinical testing with one of its lead monoclonal antibody drug conjugates, SGN-15. “We are very excited to progress into phase II with this promising anticancer agent,” stated Dr. Amy Sing, Senior Director of Medical Affairs at Seattle Genetics. Two phase II efficacy studies are being conducted, one for patients wi... 
Printer Friendly Version
09/19/00Seattle Genetics Initiates Phase I Clinical Trial of SGN-10 in Combination with Taxotere for Patients with Carcinoma
Bothell, WA – September 19, 2000 – Seattle Genetics, Inc. announced the initiation of a second phase I clinical trial with its single-chain immunotoxin, SGN-10. This study will evaluate SGN-10 in combination with Taxotere® for patients with advanced carcinoma. Aventis Pharmaceuticals, the manufacturer of Taxotere®, is co-funding the trial costs and is providing Taxotere® drug product. Taxotere® is an effective chemotherapeutic agent that is widely used in the treatment of many solid tumor ty... 
Printer Friendly Version
08/24/00Renowned Cancer Researcher Joins Seattle Genetics Board; CFO Appointed
Bothell, WA – August 1424, 2000 – Seattle Genetics today announced that Dr. Marc Lippman, the Director of the Lombardi Cancer Research Center at Georgetown University Medical School, has joined Seattle Genetics'its Board of Directors. Dr. Lippman is Professor and Chairman of the Department of Oncology, Professor of Medicine, and Chief of the Division of Hematology-Oncology at the Georgetown University Medical School. Previously, he was Head of the Medical Breast Cancer Section of the M... 
Printer Friendly Version
03/14/00Seattle Genetics, Inc. Completes $30 Million Financing to Expand Monoclonal Antibody-Based Therapy Programs
Bothell, Washington, March 14, 2000-Seattle Genetics, Inc., has raised $30 million in private financing to fight cancer. The Series B financing was led by Bank of America Ventures. Additional investors include Cascade Investment, Vulcan Ventures, Olympic Venture Partners, Sofinnova Ventures, and Indosuez Ventures. “We're very pleased to have such a strong group of investors on board as we expand all aspects of operations within the company,” stated President and C.E.O. Perry Fell. Ac... 
Printer Friendly Version